[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1590
1. Nadal SR, Horta SH, Calore EE, Manzione CR: [Outcome of treatment of anal squamous cell carcinoma and its precursor in HIV-infected patients]. Rev Assoc Med Bras (1992); 2007 Jul-Aug;53(4):365-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Outcome of treatment of anal squamous cell carcinoma and its precursor in HIV-infected patients].
  • [Transliterated title] Resultados do tratamento do carcinoma espinocelular anal e do seu precursor em doentes HIV-positivos.
  • OBJECTIVE: Incidence of anal squamous cell carcinoma is increasing mainly among HIV-positive patients.
  • Treatment consists of radiotherapy and chemotherapy, sometimes followed by tumor resection.
  • This is a report of cases treated at the "Instituto de Infectologia Emílio Ribas", Sao Paulo, Brazil.
  • Thirty patients had high grade anal intra-epithelial neoplasia (HAIN), treated with local resection, and 15 with anal canal invasive squamous cell carcinoma were first submitted to chemo radiation, while biopsies were obtained during follow-up.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Seropositivity. Neoplasm Recurrence, Local
  • [MeSH-minor] Adult. Biopsy. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Treatment Failure. Treatment Outcome. Treatment Refusal / statistics & numerical data

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17823743.001).
  • [ISSN] 0104-4230
  • [Journal-full-title] Revista da Associação Médica Brasileira (1992)
  • [ISO-abbreviation] Rev Assoc Med Bras (1992)
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


2. Scarpini C, White V, Muralidhar B, Patterson A, Hickey N, Singh N, Mullerat J, Winslet M, Davies RJ, Phillips ML, Stacey P, Laskey RA, Miller R, Nathan M, Coleman N: Improved screening for anal neoplasia by immunocytochemical detection of minichromosome maintenance proteins. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2855-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved screening for anal neoplasia by immunocytochemical detection of minichromosome maintenance proteins.
  • PURPOSE: Early detection of anal intraepithelial neoplasia (AIN) and anal squamous cell carcinoma (SCC) by screening will improve clinical outcome.
  • Assessment of anal cytology samples using routine Papanicolaou testing suffers from shortcomings in sensitivity and/or specificity, suggesting that screening tests based on biomarkers may be of value.
  • EXPERIMENTAL DESIGN: We undertook an initial immunohistochemical study of 54 anal tissue samples and validated our findings using an independent prospective cohort study of 235 anal cytology samples from 144 subjects.
  • RESULTS: In the progression from normal anal epithelium through AIN to SCC, there was increasing expression of MCM2 and MCM5, including in the superficial epithelial third, the source of the majority of cells collected by anal swab.
  • By immunocytochemistry using a mixture of anti-MCM2 and anti-MCM5 antibodies, immunopositive cells were readily identified in anal cytology samples, even at low magnification.
  • CONCLUSIONS: MCMs are promising biomarkers for improving detection of AIN and SCC in anal cytology samples.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cell Cycle Proteins / metabolism. Nuclear Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Male. Middle Aged. Minichromosome Maintenance Complex Component 2. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18843031.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105359875; United Kingdom / Medical Research Council / / MC/ U105359878; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / MCM5 protein, human; 0 / Nuclear Proteins; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


3. Uronis HE, Bendell JC: Anal cancer: an overview. Oncologist; 2007 May;12(5):524-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer: an overview.
  • Anal cancer is a rare tumor with an incidence that has been rising over the last 25 years.
  • The disease was once thought to develop as a result of chronic irritation, but it is now known that this is not the case.
  • HIV infection is also associated with anal cancer; there is a higher incidence in HIV-positive patients but the direct relationship between HIV and anal cancer has been difficult to separate from the prevalence of HPV in this population.
  • HIV infection is also associated with anal cancer; there are increasing numbers of HIV-positive patients being diagnosed with the disease.
  • Treatment of anal cancer prior to the 1970s involved abdominoperineal resection, but the standard of care is now concurrent chemoradiation therapy, with surgery reserved for those patients with residual disease.
  • We present a case of anal cancer followed by a general discussion of both risk factors and treatment.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / epidemiology. Adenocarcinoma / therapy. HIV Infections / complications. Humans. Male. Middle Aged. Neoplasm Staging. Papillomavirus Infections / complications. Risk Factors

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17522240.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


Advertisement
4. Mistrangelo M, Bellò M, Mobiglia A, Beltramo G, Cassoni P, Milanesi E, Cornaglia S, Pelosi E, Giunta F, Sandrucci S, Mussa A: Feasibility of the sentinel node biopsy in anal cancer. Q J Nucl Med Mol Imaging; 2009 Feb;53(1):3-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of the sentinel node biopsy in anal cancer.
  • AIM: Anal cancer is a rare neoplasm.
  • METHODS: Inguinal lymph node status was assessed using the sentinel node technique in 35 patients with anal cancer.
  • RESULTS: Histology revealed 23 squamous carcinomas, 10 basaloid carcinomas, 1 squamous carcinoma with basaloid areas and 1 spinocellular epithelioma associated with areas of Bowen's disease.
  • Disease stage was T1 in 5 patients, T2 in 18, T3 in 11 and T4 in 1 patient.
  • CONCLUSIONS: Given the correlation between prognosis and node involvement, sentinel node biopsy can be considered a simple method for adequate pretreatment staging of anal carcinoma.
  • [MeSH-major] Anus Neoplasms / diagnosis. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Follow-Up Studies. Humans. Inguinal Canal / pathology. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Neoplasm Staging. Recurrence

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18337684.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. De Dosso S, Martin V, Zanellato E, Frattini M, Saletti P: Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma. Tumori; 2010 Jul-Aug;96(4):627-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma.
  • There are no standard chemotherapeutic options for patients with squamous cell anal carcinoma, relapsing and progressing on palliative cisplatin-based regimens.
  • Similarly to other malignant conditions, monoclonal antibodies directed against the epidermal growth factor receptor may represent an attractive therapeutic strategy.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cetuximab. Disease Progression. Humans. Male. Neoplasm Recurrence, Local / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20968146.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 7673326042 / irinotecan; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


6. Zhang J, Martins CR, Fansler ZB, Roemer KL, Kincaid EA, Gustafson KS, Heitjan DF, Clark DP: DNA methylation in anal intraepithelial lesions and anal squamous cell carcinoma. Clin Cancer Res; 2005 Sep 15;11(18):6544-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA methylation in anal intraepithelial lesions and anal squamous cell carcinoma.
  • PURPOSE: Anal intraepithelial neoplasia is associated with human papillomavirus infection and may progress to invasive squamous cell carcinoma (SCC), which is increasing in immunocompromised patients.
  • We hypothesize that anal intraepithelial neoplasia is associated with abnormal DNA methylation and that detection of these events may be used to improve screening programs.
  • EXPERIMENTAL DESIGN: Seventy-six patients were identified who underwent anal cytology screening and subsequent biopsy at our institution between 1999 and 2004.
  • The specimens from these patients included 184 anal biopsies [normal, n = 57; low-grade squamous intraepithelial lesion (LSIL), n = 74; high-grade squamous intraepithelial lesion (HSIL), n = 41; and invasive SCC, n = 12] and 37 residual liquid-based anal cytology specimens (normal, n = 11; LSIL, n = 12; HSIL, n = 14).
  • CONCLUSIONS: Aberrant DNA methylation is a frequent event in anal HSIL and SCC.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. DNA Methylation
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adenomatous Polyposis Coli Protein / genetics. Adult. Biopsy. Carrier Proteins. Cell Adhesion Molecules. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA-Binding Proteins / genetics. Humans. Immunoglobulins / genetics. Kruppel-Like Transcription Factors. Membrane Proteins / genetics. Neoplasm Invasiveness. Neoplasm Proteins / genetics. Nuclear Proteins / genetics. O(6)-Methylguanine-DNA Methyltransferase / genetics. Polymerase Chain Reaction / methods. Protein-Serine-Threonine Kinases / genetics. Receptors, Retinoic Acid / genetics. Transcription Factors / genetics. Tumor Suppressor Protein p14ARF / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166431.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Adenomatous Polyposis Coli Protein; 0 / CADM1 protein, human; 0 / Carrier Proteins; 0 / Cell Adhesion Molecules; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA-Binding Proteins; 0 / HIC1 protein, human; 0 / Immunoglobulins; 0 / Kruppel-Like Transcription Factors; 0 / MLH1 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


7. Spugnini EP, Filipponi M, Romani L, Dotsinsky I, Mudrov N, Baroni A, Ruocco E, Laieta MT, Montesarchio V, Cassandro R, Citro G, Baldi A: Local control and distant metastasis after electrochemotherapy of a canine anal melanoma. In Vivo; 2007 Sep-Oct;21(5):897-9
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local control and distant metastasis after electrochemotherapy of a canine anal melanoma.
  • Canine anal melanoma is an aggressive neoplasm that rapidly leads to constipation in dogs, thus mimicking the behavior of their human counterpart.
  • In this paper, the successful local palliation of this neoplasm is described using cisplatin selectively driven within the tumor cells by trains of biphasic pulses.
  • The dog experienced tumor reduction with restoration of normal defecation for three months, then experienced massive dissemination to the sublumbar lymph nodes that led to intestinal obstruction and euthanasia.
  • Electrochemotherapy (ECT) is a safe palliative therapy for such neoplasm and warrants further investigations in dogs as well humans.
  • [MeSH-major] Anus Neoplasms / veterinary. Dog Diseases / drug therapy. Dog Diseases / pathology. Electrochemotherapy. Melanoma / veterinary
  • [MeSH-minor] Animals. Dogs. Female. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019432.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


8. Hosono S, Ohira M, Maeda K, Muguruma K, Nishihara T, Inoue T, Yashiro M, Hirakawa K: Synchronous adenocarcinomas of the ileum and transverse colon detected by capsule endoscopy: report of a case. Surg Today; 2006;36(7):663-5
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neither gastrointestinal endoscopy nor computed tomography showed by abnormal findings; however, a capsule endoscopy, performed to detect obscure gastrointestinal bleeding, revealed a tumor in the ileum.
  • When we tried to take biopsies of the ileal tumor by push enteroscopy via the anus, we found another tumor in the transverse colon.
  • On exploration, tumors were identified in the ileum and the transverse colon.
  • [MeSH-major] Adenocarcinoma / pathology. Capsule Endoscopy. Colonic Neoplasms / pathology. Ileal Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2005 Feb;61(2):255-61 [15729235.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):518-26 [15274064.001]
  • [Cites] Scand J Gastroenterol. 2005 Jun;40(6):725-33 [16036534.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):66-71 [6691554.001]
  • [Cites] Endoscopy. 2004 Dec;36(12):1060-6 [15578295.001]
  • [Cites] Indiana Med. 1991 Jun;84(6):392-6 [1918906.001]
  • [Cites] Arch Surg. 2002 May;137(5):564-70; discussion 570-1 [11982470.001]
  • [Cites] Can J Gastroenterol. 2004 Sep;18(9):559-65 [15457295.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2004 Jan;14(1):51-60 [15062380.001]
  • [Cites] Cancer. 1999 Dec 15;86(12):2693-706 [10594865.001]
  • [Cites] Endoscopy. 2004 Jan;36(1):32-41 [14722853.001]
  • [Cites] Gut. 2003 Aug;52(8):1122-6 [12865269.001]
  • [Cites] Int J Epidemiol. 1996 Aug;25(4):722-8 [8921448.001]
  • (PMID = 16794807.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Sueda K, Ikenaga M, Miyazaki M, Yasui M, Mishima H, Tsujie M, Omiya H, Miyamoto A, Hirao M, Takami K, Fujitani K, Nakamori S, Yoshida K, Tsujinaka T: [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2656-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of squamous cell carcinoma of the anal cancer with associated human immunodeficiency virus].
  • He presented with an anal tumor with bilateral inguinal nodal metastasis and pain in the anus; the tumor was diagnosed as stage IIIb (cA1N2M0).
  • However, CT performed 2 years after the diagnosis showed a recurrence in the hilar and mediastinal lymph node.
  • However, the treatment response was graded as progressive disease, and the treatment was changed from CDDP to mitomycin C (MMC).
  • The patient developed non-hematologic toxicity and died within 3 years of the diagnosis.
  • We report a case of squamous cell carcinoma of the anus with associated HIV infection.
  • [MeSH-major] Anus Neoplasms / complications. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. HIV Seropositivity / complications


10. Baatrup G, Bolstad M, Mortensen JH: Rigid sigmoidoscopy and MRI are not interchangeable in determining the position of rectal cancers. Eur J Surg Oncol; 2009 Nov;35(11):1169-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE:. 1) To analyse for interchangeability of rigid sigmoidoscopy and MRI in determining the distance from anus to tumour, and to determine if anterior/posterior location influences this difference.
  • 2) To analyse the effect of preoperative chemo-radiotherapy on the distance from anus to tumour.
  • RESULTS: The mean distance from the anal verge to the tumour measured by sigmoidoscopy was 82mm and by MRI 61mm (p<0.01).
  • The length of the tumours decreased by 16mm after neoadjuvant treatment, but the distance from tumour to anus increased by only 4mm. CONCLUSION:.
  • 1) MRI and sigmoidoscopy are not interchangeable in determining the distance from anus to tumour simply by correcting for the length of the anal canal.
  • 2) The gain in tumour free distance above the anus induced by neoadjuvant treatment is small.
  • [MeSH-major] Anal Canal / pathology. Magnetic Resonance Imaging / methods. Rectal Neoplasms / pathology. Sigmoidoscopy / methods

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249188.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Gorez E, Staumont G: [Epidermoid anal carcinoma]. Rev Prat; 2008 Oct 31;58(16):1783-92
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidermoid anal carcinoma].
  • [Transliterated title] Carcinome epidermoïde anal.
  • Epidermoid carcinoma of the anus is a rare cancer, and conventionally affects elderly women.
  • Warning signs of anal cancer are often non-specific.
  • The evaluation assessment should include lung X-ray, abdominal CT scan, and often pelvis MNR or anal endosonography.
  • Key prognostic factors are infiltration of the initial tumour and presence of lymph node metastasis.
  • First-line treament of anal epidermoid carcinoma is radiotherapy, combined with chemotherapy for extensive forms.
  • [MeSH-major] Anus Neoplasms. Carcinoma, Squamous Cell
  • [MeSH-minor] Age Factors. Aged. Anal Canal / pathology. Biopsy. Combined Modality Therapy. Female. Homosexuality, Male. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Risk Factors. Sex Factors

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19143150.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. Garrett K, Kalady MF: Anal neoplasms. Surg Clin North Am; 2010 Feb;90(1):147-61, Table of Contents
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal neoplasms.
  • A variety of lesions comprise tumors of the anal canal, with carcinoma in situ and epidermoid cancers being the most common.
  • Less common anal neoplasms include adenocarcinoma, melanoma, gastrointestinal stromal cell tumors, neuroendocrine tumors, and Buschke-Lowenstein tumors.
  • In this article different tumors and management of each, including a brief review of local excision for rectal cancer, are discussed in turn.
  • [MeSH-major] Anus Neoplasms / surgery
  • [MeSH-minor] Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Verrucous / diagnosis. Carcinoma, Verrucous / pathology. Humans. Intestinal Mucosa / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20109639.001).
  • [ISSN] 1558-3171
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 105
  •  go-up   go-down


13. Divis P, Vlcek P, Capov I, Divisová K, Katolická J, Vanícek J, Kotulánová E: [Evaluation of neoadjuvant chemo-radiotherapy with locally advanced rectal cancer by comparing tumour volume before and after treatment]. Klin Onkol; 2010;23(6):421-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of neoadjuvant chemo-radiotherapy with locally advanced rectal cancer by comparing tumour volume before and after treatment].
  • The aim of the study was to compare the tumour volume reduction before and after the oncological therapy in relation to the change in the CEA value and to the outcome of the histopathological evaluation of response to the treatment.
  • The tumour volume before and after the CRT, percentage reduction in the tumour volume and the relation to the change in the CAE value and the histopathological evaluation were evaluated.
  • RESULTS: The distance between the anus and the tumour was from 3 to 15 centimetres, the average value being 8.1 centimetres.
  • In 5 cases the tumour was not histologically found in the resected specimen.
  • The average tumour volume before CRT was 32.48, range 10.3-88.5, after the CRT the average volume was 20.13, range 4.7-55.1.
  • This relation however has not been proved in the N value change.
  • Only in one-third of the evaluated patients was there a positive change in both T and N classification.
  • No relation between the CEA value and the tumour volume change has been proven.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Neoadjuvant Therapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21351419.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


14. Palefsky J: Human papillomavirus and anal neoplasia. Curr HIV/AIDS Rep; 2008 May;5(2):78-85
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus and anal neoplasia.
  • Anal cancer is a rare disease in the general population, but the incidence of anal cancer is higher in certain at-risk groups, such as men who have sex with men (MSM), and immunosuppressed individuals, including those with HIV infection.
  • Among HIV-positive MSM, the incidence of anal cancer may be as high as 10 times greater than current rates of cervical cancer in the general population of women.
  • Anal cancer is associated with human papillomavirus (HPV) infection and may be preceded by high-grade anal intraepithelial neoplasia (HGAIN).
  • HGAIN and anal HPV infection are both highly prevalent in groups at risk for anal cancer.
  • Current issues include determining the effect of antiretroviral therapy on the natural history of HGAIN and the incidence of anal cancer, optimizing diagnostic and therapeutic approaches to HGAIN, and determining the potential for prophylactic HPV vaccines to prevent anal HPV infection and anal cancer in at-risk groups.
  • [MeSH-major] Anus Neoplasms. Carcinoma in Situ. Papillomavirus Infections
  • [MeSH-minor] Anus Diseases / epidemiology. Anus Diseases / virology. Female. HIV Infections / complications. Homosexuality, Male. Humans. Male. Papillomaviridae / isolation & purification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]
  • [Cites] Nat Med. 2007 Jul;13(7):857-61 [17603495.001]
  • [Cites] Dis Colon Rectum. 2007 May;50(5):565-75 [17380365.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):843-9 [11390533.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1221-7 [14520450.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):915-20 [15220697.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):56-61 [18156992.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1555-9 [14605579.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415-22 [9170415.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]
  • [Cites] Int J Colorectal Dis. 2007 Jan;22(1):1-5 [16133005.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] Virus Res. 1993 Feb;27(2):133-45 [8384765.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] MMWR Recomm Rep. 2004 Dec 17;53(RR-15):1-112 [15841069.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):969-87, ix [17996800.001]
  • [Cites] Transpl Int. 2004 Aug;17(7):366-9 [15349721.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]
  • [Cites] AIDS. 1995 Nov;9(11):1255-62 [8561979.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Lancet. 2007 Jun 30;369(9580):2161-2170 [17602732.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):432-42 [11511819.001]
  • [Cites] Br J Dermatol. 2007 Sep;157(3):523-30 [17573882.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] J Infect Dis. 2004 Nov 1;190(9):1685-91 [15478076.001]
  • [Cites] J Infect Dis. 1990 Aug;162(2):358-61 [1973695.001]
  • [Cites] Cytojournal. 2006 Mar 20;3:4 [16549010.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):320-6 [9525432.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/140-6 [16950001.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] J Am Acad Dermatol. 2004 Jun;50(6):980-1 [15153912.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Dis Colon Rectum. 2008 Jan;51(1):73-81 [18066626.001]
  • [Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):182-9 [16186736.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Oncology (Williston Park). 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim [16396154.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5 [16280701.001]
  • [Cites] Int J Cancer. 1996 Nov 27;68(5):559-64 [8938134.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24 [17380109.001]
  • (PMID = 18510893.001).
  • [ISSN] 1548-3568
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


15. Rouquie D, Lasser P, Castaing M, Boige V, Goéré D, Pignon JP, Ducreux M, Elias D, Pocard M: [Complete (R0) resection is the only valid prognostic factor in abdominoperineal resection for recurrent cancer of the anal canal (a consecutive series of 95 patients)]. J Chir (Paris); 2008 Jul-Aug;145(4):335-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete (R0) resection is the only valid prognostic factor in abdominoperineal resection for recurrent cancer of the anal canal (a consecutive series of 95 patients)].
  • [Transliterated title] Résection R0, seul facteur pronostique dans les amputations abdominopérinéales de rattrapage des cancers du canal anal (série consécutive de 95 patients).
  • INTRODUCTION: When radiation therapy fails to control cancer of the anal canal, the only therapeutic alternative is salvage abdomino-perineal resection (APR).
  • There was no prognostic difference between salvage APR for disease progression (n=55) or for late recurrence (n=40).
  • CONCLUSION: When anal cancer recurs after radiation therapy, a salvage APR is indicated.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955923.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


16. Nadal SR, Calore EE, Manzione CR, Horta SC, Ferreira AF, Almeida LV: Hypertrophic herpes simplex simulating anal neoplasia in AIDS patients: report of five cases. Dis Colon Rectum; 2005 Dec;48(12):2289-93
Hazardous Substances Data Bank. ACYCLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypertrophic herpes simplex simulating anal neoplasia in AIDS patients: report of five cases.
  • The analysis of our patients suggests that herpes simplex virus, Types 1 and 2, may cause verrucous lesions simulating neoplasia in patients with AIDS using antiretroviral therapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Anus Neoplasms / diagnosis. Herpes Simplex / diagnosis
  • [MeSH-minor] Acyclovir / therapeutic use. Adult. Anal Canal / pathology. Diagnosis, Differential. Female. Humans. Hypertrophy. Immunohistochemistry. Inflammation. Male. Middle Aged. Recurrence


17. Coquard R, Cenni JC, Artru P, Chalabreysse P, Queneau PE, Taieb S, Alessio A, Lledo G: [Definitive treatment of anal canal carcinoma with radiotherapy: adverse impact of a pre-radiation resection. A retrospective study of 57 patients treated with curative intent]. Cancer Radiother; 2009 Dec;13(8):715-20
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Definitive treatment of anal canal carcinoma with radiotherapy: adverse impact of a pre-radiation resection. A retrospective study of 57 patients treated with curative intent].
  • [Transliterated title] Radiothérapie à visée curative du carcinome du canal anal : impact défavorable d'une résection préalable. Etude rétrospective de 57 patients traités en intention curative.
  • PURPOSE: To describe retrospectively the overall survival, the cancer specific survival and the tumor control in an homogeneous series of patients with epidermoid carcinoma of the anal canal treated with definitive radiotherapy; to assess the impact of brachytherapy, chemotherapy and pre-radiotherapy resection on the risk of recurrence.
  • PATIENTS AND METHODS: From 1997 to 2007, 57 patients (pts) presenting with an epidermoid carcinoma of the anal canal (T1: 14, T2: 33, T3-4: 10, N0: 31, N1: 19, N2: 3, N3: 4, M0: 57) were treated with definitive radiotherapy by the same radiation oncologist.
  • Twelve pts had undergone a surgical resection of the tumour before radiotherapy.
  • In multivariate analysis, a pre-radiotherapy resection (p=0.084) had an inverse impact on the tumour control reaching the level of statistical significance and the use of a belly board was of marginal influence (p=0.13).
  • CONCLUSION: Radiotherapy and chemoradiation with cisplatine-based chemotherapy cure a vast majority of patients with epidermoid carcinoma of the anal canal.
  • [MeSH-major] Anal Canal / surgery. Anus Neoplasms / mortality. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Brachytherapy. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Dose Fractionation. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Patient Positioning. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19854092.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Gavioli M, Losi L, Luppi G, Iacchetta F, Zironi S, Bertolini F, Falchi AM, Bertoni F, Natalini G: Preoperative therapy for lower rectal cancer and modifications in distance from anal sphincter. Int J Radiat Oncol Biol Phys; 2007 Oct 1;69(2):370-5
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative therapy for lower rectal cancer and modifications in distance from anal sphincter.
  • Preoperative therapy can increase the rate of preserving surgery by shrinking the tumor and enhancing its distance from the anal sphincter.
  • The maximal size of the tumor and its distance from the anal sphincter were measured in millimeters before and after preoperative therapy.
  • RESULTS: Of the 90 cases, 82.5% showed tumor downsizing, varying from one-third to two-thirds or more of the original tumor mass.
  • The distance between the tumor and the anal sphincter increased in 60.2% of cases.
  • It was possible in nearly 30% of patients in whom the cancer had reached the anal sphincter before the preoperative therapy.
  • The distal margin was tumor free in these cases.
  • CONCLUSION: The results of our study have shown that in very low rectal cancer, preoperative therapy causes tumor downsizing in >80% of cases and in more than one-half enhances the distance between the tumor and anal sphincter.
  • [MeSH-major] Anal Canal / pathology. Rectal Neoplasms / pathology. Rectal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Endosonography. Female. Humans. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524570.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Hannoun L, Houry S, Huguet F, Pène F, Parc R, Schlienger M: [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)]. Cancer Radiother; 2006 Dec;10(8):572-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
  • [Transliterated title] Carcinomes épidermoïdes du canal anal traités par association concomitante de radiothérapie et de chimiothérapie. Evaluation des résultats fonctionnels.
  • PURPOSE: To evaluate our results after radiation therapy and concomitant chemotherapy in terms of local control, survival and toxicity in patients with anal cancer.
  • RESULTS: At the end of RT with concomitant chemotherapy local tumor clinical complete response rate was 83%.
  • Out of 5 local tumor relapses, 3 were salvaged with APR.
  • The overall local tumor control (LC) rate with or without salvage local treatment were 88%.
  • LC rate with a good anal function scoring (score 0 and 1) was 70%.
  • Among 43 pts who preserved their anus, 98% had a good anal function scoring.
  • The 5-year disease-free survival was 75%.
  • After multivariate analysis, 2 independent predicting factors significantly influenced the disease-free survival: HIV-positive pts (negative vs positive, P=0.032) and clinical tumor response after the first course of radiotherapy (<50% vs >or=50%, P=0.00032).
  • Late severe complication was observed in 3 pts: 2 pts with painful necrosis of the anus requiring colostomy and 1 pt with grade 3 rectal bleeding.
  • The clinical tumor response after the first course of RT and concomitant chemotherapy is probably the most important predictive factor on the disease-free survival.
  • For patients with T3 or T4 lesion and tumor regression <or=50% after the first course of radiation therapy, surgical non conservative treatment should be discussed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / pathology. Antimetabolites, Antineoplastic / administration & dosage. Brachytherapy. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Follow-Up Studies. HIV Seropositivity. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17110148.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Mistrangelo M, Mobiglia A, Bellò M, Beltramo G, Cassoni P, Mussa A: [The technique of sentinel lymph nodes in patients with anus neoplasm]. Suppl Tumori; 2005 May-Jun;4(3):S32-3
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The technique of sentinel lymph nodes in patients with anus neoplasm].
  • [Transliterated title] La tecnica del linfonodo sentinella nei pazienti affetti da neoplasia dell'ano.
  • Anal cancer is a rare neoplasm, representing 1-2% of all large bowel cancers.
  • In order to assess inguinal lymph node status we applied the sentinel node technique to patients affected by anal cancer.
  • Considering the strong correlation between prognosis and node involvement, we consider this technique an important and simple method for evaluating the lymph node status and for an adequate pre-treatment staging of anal carcinoma. fundamental in the choice of radiation plane.
  • [MeSH-major] Anus Neoplasms / pathology. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437886.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


21. Podnos YD, Tsai NC, Smith D, Ellenhorn JD: Factors affecting survival in patients with anal melanoma. Am Surg; 2006 Oct;72(10):917-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting survival in patients with anal melanoma.
  • Anal melanoma is an aggressive tumor with a predilection for early infiltration and distant spread, resulting in poor overall survival.
  • Because anal melanoma is rare, only small case series are reported in the literature, making it difficult to draw conclusions about optimal treatment and outcome.
  • The Surveillance, Epidemiology, and End Results database was used to identify patients with anal melanomas from 1973 to 2001.
  • In addition to demographics, disease extent at presentation, treatment administered, overall survival, and survival by decade of diagnosis were collected.
  • A total of 126 patients with a mean age of 69.2 years was diagnosed with anal melanoma.
  • Sixty-one per cent were female.
  • Median survival was 10 months for those with distant disease, 13 months for patients with regional spread, and 34 months for patients with local disease (P = 0.0001).
  • Five-year survival was 32 per cent, 17 per cent, and 0 per cent for patients presenting with local, regional, and distant disease, respectively (P = 0.0001).
  • Neither age at diagnosis, operation performed, nor use of radiation significantly affected survival.
  • Anal melanoma remains an uncommon but lethal disease.
  • Extent of disease correlates with overall survival.
  • [MeSH-major] Anus Neoplasms / mortality. Melanoma / mortality
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. SEER Program / statistics & numerical data. Sex Factors. Survival Rate. Treatment Outcome. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058735.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Gaertner WB, Hagerman GF, Finne CO, Alavi K, Jessurun J, Rothenberger DA, Madoff RD: Fistula-associated anal adenocarcinoma: good results with aggressive therapy. Dis Colon Rectum; 2008 Jul;51(7):1061-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fistula-associated anal adenocarcinoma: good results with aggressive therapy.
  • PURPOSE: To evaluate the clinical features, pathology, treatment, and outcome of patients with fistula-associated anal adenocarcinoma.
  • METHODS: We identified 14 patients with histologically proven fistula-associated anal adenocarcinoma.
  • The average age at time of diagnosis was 59 (range, 37-76) years.
  • Eleven patients had preexisting chronic anal fistulas.
  • Ten had Crohn's disease, and 1 had previously received pelvic radiation therapy.
  • The diagnosis of cancer was suspected during physical examination in 6 of the 14 patients (43 percent).
  • Twelve patients had extensive local disease at presentation.
  • Four patients died with metastatic disease.
  • The remaining 10 patients are alive without evidence of disease at a mean follow-up of 64.3 (range, 14-149) months.
  • CONCLUSIONS: The diagnosis of fistula-associated anal adenocarcinoma is often unsuspected.
  • [MeSH-major] Adenocarcinoma / therapy. Rectal Fistula / therapy. Rectal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Biopsy. Digestive System Surgical Procedures / methods. Drainage / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Staging. Retrospective Studies. Time Factors. Treatment Outcome. Urogenital Surgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18418652.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Chen LS, Li TY, Cao YF, Liang JL, Zhang S, Tang WZ, Tang ZJ, Gao F: [Expression of P33ING1, P53 and their relationship with apoptosis in anal canal carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Jul;9(4):338-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of P33ING1, P53 and their relationship with apoptosis in anal canal carcinoma].
  • OBJECTIVE: To explore the expressions of P33ING1, P53 and their relationships with apoptosis in anal canal carcinoma (ACC).
  • METHODS: The expressions of P33ING1, P53 proteins were measured by immunohistochemistry method (SP method), and apoptosis was detected in 42 cases with ACC, 36 cases with anal canal adenoma (ACA) or anal canal papilloma (ACP), and 40 cases with paraanal inflammatory mass(PAIM).
  • RESULTS: The positive expression rates of P33ING1 and P53 proteins were 40.5% (17/42), 97.2% (35/36) and 97.5% (39/40), 50.0% (21/42), 22.2% (8/36) and 27.5% (11/40) respectively, and the average apoptosis indexes(AI) were (10.27+/- 1.23) per thousand, (42.75+/- 0.98) per thousand and (42.67+/- 1.04) per thousand respectively in ACC, ACA or ACP and PAIM.
  • [MeSH-major] Anus Neoplasms / metabolism. Apoptosis. Carcinoma / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Nuclear Proteins / metabolism. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886119.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ING1 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


24. Roach SC, Hulse PA, Moulding FJ, Wilson R, Carrington BM: Magnetic resonance imaging of anal cancer. Clin Radiol; 2005 Oct;60(10):1111-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of anal cancer.
  • AIM: The purpose of this study was to evaluate the magnetic resonance imaging (MRI) appearances of primary and recurrent anal carcinoma, and to demonstrate the commonest patterns of local and distant disease spread.
  • METHODS: A retrospective review was performed of 27 cases of biopsy-proven anal carcinoma, where MRI was used for primary staging (9 patients) or suspected recurrence (18 patients).
  • The size, extent and signal characteristics of the anal tumour were documented.
  • Metastatic disease spread to lymph nodes, viscera and bone was recorded.
  • In all, 7 patients with recurrent disease underwent surgery and subsequent histological correlation was performed.
  • Lymph node metastases were of similar signal intensity to the anal cancer.
  • Recurrent lymph node disease involved perirectal, presacral and internal iliac nodes more commonly than did primary lymph node disease.
  • MR has a role in the preoperative evaluation and surgical planning of cases of recurrent disease following radiotherapy.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Retrospective Studies

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179172.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Sato H, Koh PK, Bartolo DC: Management of anal canal cancer. Dis Colon Rectum; 2005 Jun;48(6):1301-15
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of anal canal cancer.
  • PURPOSE: Chemoradiotherapy has replaced radical surgery as the initial treatment of choice for anal canal cancer.
  • The roles of these therapeutic modalities are discussed and recommendations on management of anal canal cancer are made based on currently available evidence.
  • METHODS: Literature on management of anal canal cancer from January 1970 to July 2003 obtained via MEDLINE was reviewed.
  • Reports on anal margin cancers were excluded.
  • In larger tumors, the addition of mitomycin C to radiotherapy and 5-fluorouracil improves local control, colostomy-free, and disease-free survival but is associated with more acute hematologic toxicity.
  • Chemoradiotherapy, including Cisplatin and 5-fluorouracil, appeared to be equal or superior to surgery as salvage therapy in patients with residual disease six weeks after initial nonsurgical treatment.
  • Few studies addressed the treatment of metastatic disease, which remains a major cause of mortality.
  • [MeSH-major] Anus Neoplasms / therapy
  • [MeSH-minor] Brachytherapy. Chemotherapy, Adjuvant. Digestive System Surgical Procedures. Dose Fractionation. Humans. Lymphatic Metastasis. Neoplasm Staging. Radiotherapy, High-Energy. Survival Rate

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793642.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 116
  •  go-up   go-down


26. von Roon AC, Tekkis PP, Clark SK, Heriot AG, Lovegrove RE, Truvolo S, Nicholls RJ, Phillips RK: The impact of technical factors on outcome of restorative proctocolectomy for familial adenomatous polyposis. Dis Colon Rectum; 2007 Jul;50(7):952-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary outcomes were major complications, pouch function, and neoplastic transformation in the anal transitional zone.
  • The incidence of polyps at the anal transitional zone was lower with handsewn than with stapled anastomosis (19 vs. 38 percent; P=0.047).
  • Handsewn ileoanal anastomosis with mucosectomy seems to reduce the incidence of subsequent neoplasia in the anal transitional zone but does not eliminate the risk of cancer.
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Incidence. Length of Stay. Male. Neoplasm Recurrence, Local / epidemiology. Postoperative Complications / epidemiology. Retrospective Studies. Risk Factors. Time Factors. Treatment Outcome


27. Hwang HJ, Bestani C, Jiménez R, Masciángioli G, Gutiérrez A, Cartelli C, Rafailovici L, Barugel M, Rodríguez G, Méndez G: [Treatment of patients with squamous cell carcinoma of the anal canal in the last 20 years in a gastroenterology hospital]. Acta Gastroenterol Latinoam; 2005;35(2):94-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of patients with squamous cell carcinoma of the anal canal in the last 20 years in a gastroenterology hospital].
  • [Transliterated title] El tratamiento de los pacientes con carcinoma epidermoide del canal anal en los últimos 20 años en nuestro hospital.
  • Anal cancers compromise only 1.5% of all digestive tumors.
  • OBJECTIVE: To collect and analyze clinical data from the medical records of all consecutive patients with squamous cell carcinoma of the anal canal (SCCAC) treated by the Oncology Section in 20 years.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16127985.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


28. Al-Sukhni W, McLeod RS, MacRae H, O'Connor B, Huang H, Cohen Z: Oncologic outcome in patients with ulcerative colitis associated with dyplasia or cancer who underwent stapled or handsewn ileal pouch-anal anastomosis. Dis Colon Rectum; 2010 Nov;53(11):1495-500
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncologic outcome in patients with ulcerative colitis associated with dyplasia or cancer who underwent stapled or handsewn ileal pouch-anal anastomosis.
  • Restorative proctocolectomy with ileal pouch-anal anastomosis is a standard surgical management of patients with ulcerative colitis who have cancer or dysplasia, but the oncologic risk of stapled anastomosis vs mucosectomy with handsewn anastomosis is debated.
  • The patients with ulcerative colitis associated with colorectal dysplasia or cancer who underwent ileal pouch-anal anastomosis between 1981 and 2009 were evaluated.
  • RESULTS: Eighty-one patients underwent stapled (n = 59) or handsewn (n = 22) ileal pouch-anal anastomosis; 52 had evidence of dysplasia and 29 had colorectal cancer (24 colon; 5 rectum) at the time of surgery.
  • CONCLUSIONS: Performing a stapled ileal pelvic anal anastomosis does not appear to be inferior to mucosectomy and handsewn anastomosis in oncologic outcome, and it seems appropriate in patients with ulcerative colitis associated with coexisting dysplasia or cancer.
  • [MeSH-major] Colitis, Ulcerative / surgery. Colonic Pouches. Colorectal Neoplasms / surgery. Precancerous Conditions / surgery. Proctocolectomy, Restorative. Suture Techniques
  • [MeSH-minor] Adolescent. Adult. Analysis of Variance. Anastomosis, Surgical. Chi-Square Distribution. Child. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Statistics, Nonparametric. Surgical Stapling. Treatment Outcome


29. Poizot-Martin I, Henry M, Benhaim S, Obry-Roguet V, Figarella D, Tamalet C: High level of HPV 16 and 18 DNA load in anal swabs from male and female HIV-1 infected patients. J Clin Virol; 2009 Apr;44(4):314-7
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High level of HPV 16 and 18 DNA load in anal swabs from male and female HIV-1 infected patients.
  • BACKGROUND: Despite HAART, the prevalence and incidence of anal cancer in HIV-infected individuals have increased.
  • Recently, the relationship between the severity of cervical lesions and oncogenic HPV load was demonstrated; however, few studies have assessed the level and the significance of oncogenic HPV load in patients at risk for anal neoplasia.
  • OBJECTIVES: To assess HPV genotypes and HPV 16/18 DNA load in HIV-1 infected patients at risk for anal neoplasia.
  • STUDY DESIGN: Cross-sectional pilot study from male and female HIV-1 infected individuals at risk for anal neoplasia in an outpatient HIV Clinical Unit of Marseilles university Hospitals.
  • RESULTS: Anal HPV was found in 79% of the patients whereas high-risk (HR) HPV types and infection with multiple HPV types were found in 83% and 61% of the patients, respectively.
  • CONCLUSIONS: Longitudinal studies are needed to evaluate the link between high anal HPV DNA load and progression to anal squamous intraepithelial lesions and anal cancer.
  • [MeSH-major] Anal Canal / virology. DNA, Viral / isolation & purification. HIV Infections / complications. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Papillomavirus Infections / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269245.001).
  • [ISSN] 1873-5967
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


30. Christensen AF, Nielsen MB, Svendsen LB, Engelholm SA: Three-dimensional anal endosonography may improve detection of recurrent anal cancer. Dis Colon Rectum; 2006 Oct;49(10):1527-32
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional anal endosonography may improve detection of recurrent anal cancer.
  • PURPOSE: In our center since 2001, follow-up examination has included three-dimensional endosonography in all patients with suspicion of local recurrence of anal cancer.
  • METHODS: This prospective study included 38 consecutive patients who have had anal carcinoma and were investigated using three-dimensional endosonography in combination with anoscopy and digital rectal examination at Rigshospitalet from July 2001 to January 2005 under suspicion of local recurrence.
  • The observers scored each examination according to a five-point scale in which a score from 1 to 3 was regarded as benign endosonographic findings and a score from 4 to 5 was regarded as malignant endosonographic findings.
  • The endosonographic diagnosis for each examination was compared with histologic evaluation or when no biopsy had been taken with a follow-up period of at least six months.
  • CONCLUSIONS: This study indicates that three-dimensional endosonography surpasses two-dimensional endosonography in the evaluation of patients with suspicion of local recurrence of anal cancer especially in combination with anoscopy and digital rectal examination.
  • [MeSH-major] Anal Canal / ultrasonography. Anus Neoplasms / ultrasonography. Endosonography / methods. Imaging, Three-Dimensional. Neoplasm Recurrence, Local / ultrasonography

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988854.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Wright ZM, Fryer JS, Calise DV, Oliveira FN: Carboplatin chemotherapy in a cat with a recurrent anal sac apocrine gland adenocarcinoma. J Am Anim Hosp Assoc; 2010 Jan-Feb;46(1):66-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin chemotherapy in a cat with a recurrent anal sac apocrine gland adenocarcinoma.
  • The mass was incompletely excised, and histological assessment resulted in a diagnosis of anal sac adenocarcinoma.
  • Necropsy confirmed the original diagnosis as well as metastasis to the regional lymph nodes and lungs.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / veterinary. Anal Gland Neoplasms / drug therapy. Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Cat Diseases / drug therapy
  • [MeSH-minor] Anal Sacs / pathology. Animals. Cats. Fatal Outcome. Lung Neoplasms / secondary. Lung Neoplasms / veterinary. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local / veterinary

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20045840.001).
  • [ISSN] 1547-3317
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


32. Mistrangelo M, Pelosi E, Bellò M, Castellano I, Cassoni P, Ricardi U, Munoz F, Racca P, Contu V, Beltramo G, Morino M, Mussa A: Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of inguinal node metastases in patients with anal cancer. Int J Radiat Oncol Biol Phys; 2010 May 1;77(1):73-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of inguinal node metastases in patients with anal cancer.
  • BACKGROUND: Inguinal lymph node metastases in patients with anal cancer are an independent prognostic factor for local failure and overall mortality.
  • CONCLUSIONS: In this series of patients with anal cancer, inguinal sentinel node biopsy was superior to PET-CT for staging inguinal lymph nodes.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / radionuclide imaging. Lymph Nodes / pathology. Lymph Nodes / radionuclide imaging. Positron-Emission Tomography / methods. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy / methods. False Positive Reactions. Female. Fluorodeoxyglucose F18. Humans. Inguinal Canal. Lymphatic Metastasis / diagnosis. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging / methods. Radiopharmaceuticals. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632066.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


33. Bernard JE, Butler MO, Sandweiss L, Weidner N: Anal intraepithelial neoplasia: correlation of grade with p16INK4a immunohistochemistry and HPV in situ hybridization. Appl Immunohistochem Mol Morphol; 2008 May;16(3):215-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal intraepithelial neoplasia: correlation of grade with p16INK4a immunohistochemistry and HPV in situ hybridization.
  • Accurate diagnosis and grading of anal intraepithelial neoplasia (AIN) can be problematic, especially in separating AIN from anal transitional-zone epithelium.
  • To investigate if p16 would help in more accurately diagnosing and grading AIN, particularly when attempting to distinguish benign transitional-zone epithelium from high-grade AIN, we separately assessed these stains in a blinded manner on a large number of consecutive anal biopsies and anal tissues and correlated the findings with the diagnosis and grade of AIN.
  • One hundred thirty-three consecutive anal tissue specimens, from 128 patients were studied.
  • One hundred and eight were anal biopsies and 25 were hemorrhoidectomy specimens.
  • We conclude that the correlation between AIN and p16 and HPV is strong enough to be quite useful in distinguishing true AIN from benign mimics, such as benign transitional-zone epithelium.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301250.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA Probes, HPV
  •  go-up   go-down


34. Doniec JM, Schniewind B, Kovács G, Kahlke V, Loehnert M, Kremer B: Multimodal therapy of anal cancer added by new endosonographic-guided brachytherapy. Surg Endosc; 2006 Apr;20(4):673-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal therapy of anal cancer added by new endosonographic-guided brachytherapy.
  • BACKGROUND: The most appropriate therapy for anal cancer is external beam radiotherapy (EBRT) combined with chemotherapy (CTX).
  • We report on our experience of combined modality therapy of anal cancer and transrectal ultrasound (TRUS)-guided high-dose rate (HDR) afterloading therapy, referring to results of a study published in 1998 by the coauthors.
  • METHODS: From 1993 to 2001, 50 patients with anal cancer were treated.
  • RESULTS: In five patients (10%), tumor recurrence occurred or the tumor did not respond to therapy, and four (8%) developed distant lymph nodes or organ metastases.
  • Specific disease-related 5-year survival was 82%.
  • CONCLUSIONS: TRUS-guided brachytherapy permits excellent local tumor control and results in minimal treatment-related morbidity.
  • Consequently, TRUS-guided brachytherapy may be a useful addition to current combined modality treatment regimens for anal cancer.
  • [MeSH-major] Anus Neoplasms / diagnostic imaging. Anus Neoplasms / radiotherapy. Brachytherapy. Endosonography
  • [MeSH-minor] Aged. Combined Modality Therapy. Digestive System Surgical Procedures / adverse effects. Fecal Incontinence / epidemiology. Fecal Incontinence / etiology. Female. Humans. Incidence. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / surgery. Retreatment. Salvage Therapy. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Cancer. 1983 Apr 1;51(7):1291-6 [6825051.001]
  • [Cites] Dis Colon Rectum. 1998 Apr;41(4):441-50 [9559628.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):575-81 [9486607.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1569-79 [8156483.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 1;27(1):59-66 [8365944.001]
  • [Cites] Dis Colon Rectum. 1984 Dec;27(12):763-6 [6499614.001]
  • [Cites] Cancer. 1983 May 15;51(10):1830-7 [6831349.001]
  • [Cites] Radiother Oncol. 1996 Nov;41(2):131-4 [9004355.001]
  • [Cites] Cancer. 1981 Jul 15;48(2):411-5 [7237411.001]
  • [Cites] Dis Colon Rectum. 1998 Feb;41(2):169-76 [9556240.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] Cancer Radiother. 1999 Nov-Dec;3(6):461-7 [10630158.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):778-82 [7172946.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1226-33 [10189126.001]
  • [Cites] Dis Colon Rectum. 1991 Jun;34(6):482-6 [1903692.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):313-24 [9069302.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1736-40 [8448738.001]
  • (PMID = 16432657.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


35. Rödel C: [Radiochemotherapy for locally advanced anal cancer]. Onkologie; 2010;33 Suppl 4:24-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiochemotherapy for locally advanced anal cancer].
  • [Transliterated title] Radiochemotherapie des lokal fortgeschrittenen Analkarzinoms.
  • Standard treatment for anal canal cancer is definitive radiochemotherapy (RCT) with 5-fluorouracil plus mitomycin C.
  • Because anal cancer overexpresses the epidermal growth factor receptor (EGFR), and a KRAS wild type is usually present, treatment with the EGFR antibody cetuximab is potentially interesting.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Neoadjuvant Therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Cetuximab. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Clinical Trials as Topic. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Gene Expression Regulation, Neoplastic / genetics. Humans. Mitomycin / administration & dosage. Mitomycin / adverse effects. Neoplasm Staging. Prognosis. Proto-Oncogene Proteins / genetics. Radiotherapy, Adjuvant. Receptor, Epidermal Growth Factor / genetics. ras Proteins / genetics

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20431309.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 50SG953SK6 / Mitomycin; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 13
  •  go-up   go-down


36. Haboubi NY, Edilbe MW, Hill J: Justification for staging of epidermoid anal carcinoma after salvage surgery: a pathological guideline. Colorectal Dis; 2007 Mar;9(3):238-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Justification for staging of epidermoid anal carcinoma after salvage surgery: a pathological guideline.
  • The currently accepted first line treatment for epidermoid anal cancer is chemoradiotherapy (CRT).
  • Tumour size and adjacent organ involvement are the key in the pretreatment assessment for T1-T4 tumours respectively.
  • Residual or recurrent disease following initial CRT, is best treated by salvage anorectal excision.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Neoplasm Staging / standards

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17298622.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Haberstich R, Tuech JJ, Wilt M, Rodier JF: Anal localization as first manifestation of metastatic ductal breast carcinoma. Tech Coloproctol; 2005 Dec;9(3):237-8
Hazardous Substances Data Bank. ANASTROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal localization as first manifestation of metastatic ductal breast carcinoma.
  • Nonspecific presenting symptoms, death of the patients caused by other more frequent metastases, and variable radiographic features mimicking primary neoplasms cause a clinical underestimation of this pathology.
  • This is to our knowledge, the first recorded instance of an anal metastasis from IDC.
  • [MeSH-major] Anus Neoplasms / secondary. Anus Neoplasms / therapy. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Nitriles / administration & dosage. Triazoles / administration & dosage
  • [MeSH-minor] Aged. Biopsy, Needle. Chemotherapy, Adjuvant. Colectomy / methods. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neoplasm Staging. Rare Diseases. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16328121.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Nitriles; 0 / Triazoles; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down


38. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A: Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum; 2009 Apr;52(4):624-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base.
  • PURPOSE: The objective of this study was to assess survival and prognostic factors for anal carcinoma in the population.
  • METHODS: Patients with squamous-cell carcinoma of the anal canal were identified from the National Cancer Data Base (1985-2000).
  • RESULTS: Nineteen thousand one hundred ninety-nine patients with anal carcinoma were identified (Stage I, 25.3 percent; Stage II, 51.8 percent; Stage III, 17.1 percent; Stage IV, 5.7 percent).
  • On multivariable analysis, patients with anal carcinoma had a higher risk of death if they were male, >or=65 years old, black, living in lower median incomes areas, and had more advanced T stage tumors, nodal or distant metastases, or poorly differentiated cancers (P < 0.0001).
  • There was not a significant difference in survival by hospital type or year of diagnosis.
  • CONCLUSION: Although tumor characteristics and staging affect prognosis, patient factors, such as gender, race, and socioeconomic status, are also important prognostic factors for squamous-cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / mortality. Carcinoma, Squamous Cell / mortality
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404066.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Christensen AF, Nyhuus B, Nielsen MB: Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer. Dis Colon Rectum; 2009 Mar;52(3):484-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer.
  • PURPOSE: This study was designed to evaluate the interobserver and intraobserver agreement of two-dimensional (2-D) and three-dimensional (3-D) anal endosonography for the detection of local recurrence anal carcinoma.
  • METHODS: Thirty-six patients were treated for anal carcinoma, and seven had recurrent disease.
  • The observers scored each examination according to the following scale regarding presence of local recurrence: 1 = no finding/benign findings; 2 = properly benign findings; 3 = suspicious findings/malignant findings.
  • CONCLUSIONS: Three-dimensional endosonography proved to have significantly better interobserver and intraobserver agreement than 2-D endosonography concerning detection of recurrent anal cancer.
  • [MeSH-major] Anus Neoplasms / ultrasonography. Endosonography. Neoplasm Recurrence, Local / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / ultrasonography. Female. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Observer Variation. Retrospective Studies

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333050.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Lund JA, Wibe A, Sundstrom SH, Haaverstad R, Kaasa S, Myrvold HE: Anal carcinoma in mid-Norway 1970-2000. Acta Oncol; 2007;46(7):1019-26
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma in mid-Norway 1970-2000.
  • The treatment of anal carcinoma changed from surgery to chemoradiotherapy 20-25 years ago.
  • The aim of this observational study was to compare surgery with chemoradiotherapy with regard to side effects, local recurrence and survival during and after the implementation of a new treatment policy for anal carcinoma.
  • The study includes all 111 patients with anal carcinoma diagnosed between 1970 and 2000 in mid-Norway.
  • Late side effects were moderate after combined therapy; only one patient preferred getting a stoma due to radiation damage of the anal sphincter.
  • The change of strategy for anal cancer treatment from surgery to combined therapy has probably reduced local recurrence and improved survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma / therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17882558.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


46. Rowe NM, Meisher IE, Sheka KP, Bopaiah V: Leiomyosarcoma of the anal canal: a case report. Int J Surg; 2007 Oct;5(5):345-50
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma of the anal canal: a case report.
  • BACKGROUND: Leiomyosarcoma (LMS) of the colon, rectum, and anus comprise less than 0.1% of all rectal malignancies with isolated leiomyosarcomas of the anal canal representing only eight reported cases.
  • CASE REPORT: An 80-year-old male presented with a complaint of bright red blood per rectum, constipation, and a subjective history of a rectal mass diagnosed 3 years prior.
  • Pertinent findings on physical exam included a hard, non-mobile mass in the anus which biopsy showed to be a LMS.
  • At the time of operation the perianal mass extended from the external sphincters into the anal canal.
  • CONCLUSION: Isolated LMS of the anus is an extremely rare finding with only eight previous reports in the world literature.
  • LMS is an aggressive tumor with a high local recurrence rate as well as significant hematogenous spread.
  • [MeSH-major] Anus Neoplasms / surgery. Leiomyosarcoma / surgery. Neoplasm Recurrence, Local / therapy

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561465.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


47. Parry NM: Anal sac gland carcinoma in a cat. Vet Pathol; 2006 Nov;43(6):1008-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal sac gland carcinoma in a cat.
  • Histologically, this was a poorly demarcated, unencapsulated, multilobulated neoplasm that invaded surrounding perirectal skeletal muscle bundles.
  • Mitotic figures were 2 per 40 x objective field.
  • These microscopic features are consistent with anal sac gland carcinoma.
  • This is the second report of this neoplasm in a cat.
  • [MeSH-major] Anal Gland Neoplasms / pathology. Anal Sacs / pathology. Carcinoma / veterinary. Cat Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17099161.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Borzomati D, Valeri S, Ripetti V, Vincenzi B, Rabitti C, Persichetti P, Valentini V, Trodella L, Caricato M, Coppola R: Persisting perianal ulcer after radiotherapy for anal cancer: recurrence of disease or late radiation-related complication? Hepatogastroenterology; 2005 May-Jun;52(63):780-4
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persisting perianal ulcer after radiotherapy for anal cancer: recurrence of disease or late radiation-related complication?
  • We report the case of a 47-year-old HIV-negative male affected by a perianal ulcer which occurred after chemoradiation delivered for anal cancer.
  • In spite of a negative biopsy the lesion was highly suspected to be a disease recurrence.
  • Uncontrollable pain and anal stenosis were also present; abdominoperineal resection with a large excision of perianal tissues and reconstruction with bilateral musculocutaneous gracilis flaps was therefore performed.
  • Histology did not confirm tumor recurrence.
  • Thirteen months after surgery, the patient is still alive and free of disease.
  • The introduction of radiotherapy and concomitant chemotherapy has revolutionized the treatment of anal cancer, avoiding demolitive surgery in a large subset of patients.
  • Radionecrosis is an uncommon but potentially devastating event occurring in up to 10% of patients undergoing radiotherapy for anal cancer.
  • It causes clinical (pain, anal stenosis, mucositis and diarrhea) and diagnostic problems (recurrence vs. benign post-attinic lesion).
  • [MeSH-major] Anus Neoplasms / radiotherapy. Neoplasm Recurrence, Local / diagnosis. Perineum / radiation effects. Radiodermatitis / diagnosis. Ulcer / diagnosis
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / surgery. Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Surgical Flaps

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966204.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


49. Hoots BE, Palefsky JM, Pimenta JM, Smith JS: Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer; 2009 May 15;124(10):2375-83
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions.
  • A systematic review was conducted of HPV type distribution in anal cancer and anal high-grade and low-grade squamous intraepithelial lesions (HSIL and LSIL).
  • A total of 1,824 cases were included: 992 invasive anal cancers, 472 HSIL cases and 360 LSIL cases.
  • Crude HPV prevalence in anal cancer, HSIL, and LSIL was 71, 91 and 88%, respectively.
  • HPV16/18 prevalence was 72% in invasive anal cancer, 69% in HSIL and 27% in LSIL.
  • The HPV 16 and/or 18 prevalence in invasive anal cancer cases was similar to that reported in invasive cervical cancer.
  • If ongoing clinical trials show efficacy in preventing anal HPV infection and associated anal lesions, prophylactic HPV vaccines may play an important role for the primary prevention of these cancers in both genders.
  • [MeSH-major] Anus Neoplasms / virology. Carcinoma in Situ / virology. Papillomaviridae / isolation & purification
  • [MeSH-minor] DNA, Viral / genetics. Female. Humans. Male. Neoplasm Invasiveness. Species Specificity

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 19189402.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Number-of-references] 26
  •  go-up   go-down


50. Heitland W: [Diagnosis and therapy for anal carcinoma]. Chirurg; 2008 Feb;79(2):183-91; quiz 192
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and therapy for anal carcinoma].
  • [Transliterated title] Diagnostik und Therapie des Analkarzinoms.
  • Of all carcinomas in the anal canal, 75-80% are squamous cell carcinomas-the remaining 25% being adenocarcinomas.
  • Carcinomas of the anal margin are to be differentiated from basal cell carcinomas and Paget's and Bowen's diseases.
  • More than 80% of anal carcinomas show high-risk HP viruses.
  • Every suspicious lesion in the anal canal and margins must be examined histologically.
  • Primary radiochemotherapy is the first treatment option for epidermoid carcinomas of the anal canal and anal margin.
  • Surgery is reserved for the primary biopsy or excision of small tumors and for salvage abdominoperineal resection in patients with tumor persistence or local recurrence after radiochemotherapy.
  • [MeSH-major] Anus Neoplasms / surgery
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Combined Modality Therapy. Humans. Lymph Node Excision. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Prognosis. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1984 Aug 1;54(3):411-5 [6329504.001]
  • [Cites] J Gastrointest Surg. 2001 Jul-Aug;5(4):383-7 [11985979.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):45-51 [12504657.001]
  • [Cites] Dis Colon Rectum. 2005 Jan;48(1):16-22 [15690652.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Dis Colon Rectum. 2004 Jul;47(7):1136-44 [15164245.001]
  • [Cites] World J Surg. 2005 Nov;29(11):1452-7 [16222445.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2062-8 [6435851.001]
  • [Cites] Colorectal Dis. 2006 Feb;8(2):124-9 [16412072.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):479-85 [15890590.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):478-83 [17103253.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Am J Surg. 1985 Jan;149(1):95-101 [3966647.001]
  • [Cites] Ann Surg. 1976 Oct;184(4):422-8 [189707.001]
  • [Cites] Ann Surg. 1994 Jul;220(1):40-9 [8024357.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • (PMID = 18227955.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


51. de Jong JS, Beukema JC, van Dam GM, Slart R, Lemstra C, Wiggers T: Limited value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: a prospective study with long-term follow-up. Ann Surg Oncol; 2010 Oct;17(10):2656-62
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: a prospective study with long-term follow-up.
  • BACKGROUND: Selection of patients with anal cancer for groin irradiation is based on tumor size, palpation, ultrasound, and fine needle cytology.
  • Current staging of anal cancer may result in undertreatment in small tumors and overtreatment of large tumors.
  • This study reports the feasibility of the sentinel lymph node biopsy (SLNB) in patients with anal cancer and whether this improves the selection for inguinal radiotherapy.
  • METHODS: A total of 50 patients with squamous anal cancer were evaluated prospectively.
  • Patients without a SLNB (n = 29) received irradiation of the inguinal lymph nodes based on lymph node status, tumor size, and location of the primary tumor.
  • However, 2 patients with a tumor-free SLN and no inguinal irradiation developed lymph node metastases after 12 and 24 months, respectively.
  • CONCLUSIONS: We conclude that SLNB in anal cancer is technically feasible.
  • However, because of the occurrence of inguinal lymph node metastases after a tumor-negative SLNB, introduction of this procedure as standard of care in all patients with anal carcinoma should be done with caution to avoid undertreatment of patient who otherwise would benefit from inguinal radiotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Anal Canal / pathology. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1989 Sep;169(3):238-42 [2672386.001]
  • [Cites] J Ultrasound Med. 1993 May;12(5):255-8 [8345551.001]
  • [Cites] World J Surg. 1997 Mar-Apr;21(3):270-4 [9015169.001]
  • [Cites] Ann Surg Oncol. 1997 Mar;4(2):156-60 [9084853.001]
  • [Cites] World J Surg. 1997 Oct;21(8):788-92; discussion 793 [9327667.001]
  • [Cites] J Am Coll Surg. 1997 Nov;185(5):494-505 [9358099.001]
  • [Cites] BJU Int. 2005 Mar;95(4):517-21 [15705071.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):31-5 [16372147.001]
  • [Cites] Dermatol Surg. 2006 Nov;32(11):1309-21 [17083582.001]
  • [Cites] Ann Surg Oncol. 2006 Nov;13(11):1511-6 [17009151.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):376-82 [18453023.001]
  • [Cites] Eur J Surg Oncol. 2008 Aug;34(8):890-4 [18178364.001]
  • [Cites] Br J Radiol. 2009 Jan;82(973):41-8 [19095815.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2009 Feb;53(1):3-8 [18337684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1007-13 [11240241.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]
  • [Cites] Radiother Oncol. 2001 Oct;61(1):15-22 [11578724.001]
  • [Cites] ANZ J Surg. 2002 Sep;72(9):651-4 [12269917.001]
  • [Cites] Scand J Surg. 2002;91(4):336-8 [12558082.001]
  • [Cites] Dis Colon Rectum. 2003 Aug;46(8):1027-9; discussion 1030-1 [12907894.001]
  • [Cites] Dis Colon Rectum. 2003 Aug;46(8):1032-7 [12907896.001]
  • [Cites] Onkologie. 2003 Oct;26(5):456-60 [14605462.001]
  • [Cites] Cancer Radiother. 2003 Nov;7 Suppl 1:85s-90s [15124549.001]
  • [Cites] Am J Surg. 1984 Jan;147(1):43-8 [6691550.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):114-25 [6326995.001]
  • [Cites] Dis Colon Rectum. 1987 May;30(5):324-33 [3568920.001]
  • (PMID = 20865825.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2941712
  •  go-up   go-down


52. Mai SK, Welzel G, Haegele V, Wenz F: The influence of smoking and other risk factors on the outcome after radiochemotherapy for anal cancer. Radiat Oncol; 2007;2:30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of smoking and other risk factors on the outcome after radiochemotherapy for anal cancer.
  • We evaluated the effect of smoking during radiochemotherapy on the outcome for patients with anal cancer.
  • METHODS: Sixty-eight patients (34 smokers, 34 non-smokers) treated by radiochemotherapy for anal cancer were analysed.
  • The effect of smoking during radiochemotherapy and other risk factors (gender, T- and N category, tumor site, dose, therapy protocol) on disease-specific survival (DSS), local control (LC) and colostomy free survival (CFS) was evaluated.
  • CONCLUSION: Even though our evaluation reached statistical significance only in univariate analysis, we suggest, that the role of smoking during radiochemotherapy for anal cancer should not be ignored.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Smoking / adverse effects
  • [MeSH-minor] Adult. Aged. Colostomy / statistics & numerical data. Disease-Free Survival. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Retrospective Studies. Risk Factors. Sex Characteristics. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2428-36 [16634096.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):159-63 [8417381.001]
  • [Cites] Carcinogenesis. 1993 Feb;14(2):329-32 [8382117.001]
  • [Cites] FASEB J. 1993 Aug;7(11):1045-51 [8370474.001]
  • [Cites] Rev Med Interne. 1993 May;14(5):340-9 [8235150.001]
  • [Cites] J Cutan Med Surg. 2001 Jul-Aug;5(4):323-8 [11907844.001]
  • [Cites] Head Neck. 2002 Dec;24(12):1031-7 [12454940.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1274-83 [12873671.001]
  • [Cites] Cancer Causes Control. 2003 Nov;14(9):837-46 [14682441.001]
  • [Cites] Mutat Res. 2004 Jun 13;560(2):167-72 [15157654.001]
  • [Cites] Dis Colon Rectum. 2004 Jul;47(7):1136-44 [15164245.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] JAMA. 1980 Nov 14;244(19):2175-9 [6252357.001]
  • [Cites] Int J Cancer. 1981 Aug 15;28(2):153-6 [7319670.001]
  • [Cites] J Natl Cancer Inst. 1982 Mar;68(3):395-9 [6950166.001]
  • [Cites] Can Med Assoc J. 1982 Oct 15;127(8):727-9 [7139487.001]
  • [Cites] Cancer. 1984 Mar 15;53(6):1285-93 [6692319.001]
  • [Cites] Clin Exp Immunol. 1985 Aug;61(2):459-66 [2931227.001]
  • [Cites] Cancer. 1989 May 15;63(10):2060-5 [2702575.001]
  • [Cites] Cancer Res. 1989 Jul 15;49(14):4024-9 [2736543.001]
  • [Cites] Int J Colorectal Dis. 1989 Dec;4(4):234-43 [2614221.001]
  • [Cites] FASEB J. 1994 Jun;8(9):654-60 [8005393.001]
  • [Cites] Gynecol Obstet Invest. 1995;39(1):34-8 [7890250.001]
  • [Cites] Gynecol Obstet Invest. 1996;41(4):253-9 [8793496.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):575-81 [9261527.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 21;91(8):708-15 [10218509.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):92-102 [15629599.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • (PMID = 17711570.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2078591
  •  go-up   go-down


53. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Halverson AL: Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States. Ann Surg Oncol; 2008 Jul;15(7):1948-58
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States.
  • BACKGROUND: Over the past two decades, recommended treatment for squamous cell carcinoma of the anal canal has shifted from surgery to primary chemoradiation.
  • Resection is now reserved for persistent or recurrent disease.
  • METHODS: From the National Cancer Data Base (1985-2005), 38,882 patients with anal canal cancer were identified.
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Squamous Cell / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Female. Guideline Adherence. Humans. Male. Neoplasm Staging. Survival Rate. Treatment Outcome. United States

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414951.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Elshazly WG, Farouk M, Samy M: Preoperative concomitant radiotherapy with oral capecitabine in advanced rectal cancer within 6 cm from anal verge. Int J Colorectal Dis; 2009 Apr;24(4):401-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative concomitant radiotherapy with oral capecitabine in advanced rectal cancer within 6 cm from anal verge.
  • AIM: This study aimed to evaluate the role preoperative chemo-radiotherapy with oral capacitabine for advanced low rectal cancer within 6 cm of anal verge.
  • There were two disease-linked deaths, one controlled regional recurrence, two evolutive patients (pulmonary metastases), and 22 disease-free patients.
  • [MeSH-major] Anal Canal / pathology. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Preoperative Care. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Administration, Oral. Adult. Capecitabine. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Patient Compliance. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4620-5 [17008704.001]
  • [Cites] Br J Surg. 1978 Oct;65(10):695-8 [709078.001]
  • [Cites] Surgery. 1997 Oct;122(4):779-84; discussion 784-5 [9347856.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):301-8 [9440757.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1166-9 [1682591.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Feb 1;40(3):569-74 [9486606.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1114-23 [16971718.001]
  • [Cites] Anticancer Res. 2007 Jan-Feb;27(1B):541-5 [17348439.001]
  • [Cites] Br J Surg. 1994 Sep;81(9):1376-8 [7953423.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1735-43 [14630678.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] Neth J Med. 2008 Feb;66(2):71-6 [18292610.001]
  • [Cites] Br J Surg. 1982 Jun;69(6):301-4 [7082951.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):67-73 [7826163.001]
  • [Cites] Dis Colon Rectum. 1997 May;40(5):515-22 [9152176.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2948-53 [10537364.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):762-71 [17011451.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3537-41 [9817272.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Ann Oncol. 2006 Feb;17(2):246-51 [16282246.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Nov 15;27(4):779-83 [8244805.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):125-32 [10761791.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):346-53 [15913913.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(4):291-7 [10755317.001]
  • [Cites] Dis Colon Rectum. 1999 Oct;42(10):1272-5 [10528763.001]
  • [Cites] Br J Cancer. 2007 Nov 19;97(10):1333-7 [17987042.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):3983-91 [12351595.001]
  • [Cites] Dis Colon Rectum. 1999 Sep;42(9):1168-75 [10496557.001]
  • [Cites] Eur J Cancer. 2002 Feb;38 Suppl 2:15-20 [11841931.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):131-9 [9075745.001]
  • [Cites] Br J Cancer. 2004 Sep 13;91(6):1019-24 [15305186.001]
  • (PMID = 19084971.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


55. Iesalnieks I, Gaertner WB, Glass H, Strauch U, Hipp M, Agha A, Schlitt HJ: Fistula-associated anal adenocarcinoma in Crohn's disease. Inflamm Bowel Dis; 2010 Oct;16(10):1643-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fistula-associated anal adenocarcinoma in Crohn's disease.
  • BACKGROUND: Adenocarcinoma arising from perianal fistulae in patients with Crohn's disease (CD) is rare.
  • We present 6 patients with CD and fistula-associated anal adenocarcinoma (FAAA) and a systematic review of published series.
  • The average age at time of diagnosis was 45.5 years.
  • Four patients died with metastatic disease, 1 is alive with pelvic recurrence at 55 months, and 1 is alive without evidence of disease at 19 months follow-up.
  • Mean delay of cancer diagnosis was 11 months.
  • Thirteen of 15 patients with node-positive tumors died with recurrent disease following surgery.
  • [MeSH-major] Adenocarcinoma, Mucinous / etiology. Anus Neoplasms / etiology. Crohn Disease / complications. Rectal Fistula / etiology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate


56. Crehange G, Bosset M, Lorchel F, Dumas JL, Buffet-Miny J, Puyraveau M, Mercier M, Bosset JF: Combining cisplatin and mitomycin with radiotherapy in anal carcinoma. Dis Colon Rectum; 2007 Jan;50(1):43-9
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combining cisplatin and mitomycin with radiotherapy in anal carcinoma.
  • We tested the feasibility of chemoradiation in anal carcinoma with mitomycin and cisplatin in a phase II study.
  • METHODS: Twenty-one patients with locally advanced anal carcinoma (15 women, 6 men) were treated.
  • CONCLUSIONS: Combining radiation with mitomycin and cisplatin in patients with locally advanced anal cancer is feasible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma / drug therapy. Carcinoma / radiotherapy. Cisplatin / administration & dosage. Mitomycin / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Drug Administration Schedule. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy Dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089083.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


57. Eng C: Anal cancer: current and future methodology. Cancer Invest; 2006 Aug-Sep;24(5):535-44
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer: current and future methodology.
  • Despite the small number of patients affected by carcinoma of the anal canal it remains one of the most challenging cancers to treat.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Clinical Trials as Topic. Fluorouracil / therapeutic use. HIV Infections / complications. Humans. Mitomycin / therapeutic use. Neoadjuvant Therapy. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm, Residual. Papillomavirus Infections / complications

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939964.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 64
  •  go-up   go-down


58. Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, Chang GJ, Bhosale P, Delclos ME, Krishnan S, Janjan NA, Crane CH: Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys; 2007 Jul 1;68(3):794-800
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors and patterns of recurrence after definitive chemoradiation for anal cancer.
  • PURPOSE: To evaluate patterns of locoregional failure, and predictors of recurrence and survival in patients treated with chemoradiation for anal cancer.
  • METHODS AND MATERIALS: Between September 1992 and August 2004, 167 patients with nonmetastatic squamous cell anal carcinoma were treated with definitive chemoradiation.
  • RESULTS: The estimated 3-year rates of locoregional control, distant control, disease-free survival, and overall survival were 81%, 88%, 67%, and 84%, respectively.
  • Multivariate analysis showed that higher T stage and N stage independently predicted for a higher rate of locoregional failure; higher N stage and basaloid subtype independently predicted for a higher rate of distant metastasis; and higher N stage and positive human immunodeficiency virus status independently predicted for a lower rate of overall survival.
  • Among the patients who had locoregional failure, 18 (75%) had failure involving the anus or rectum, 5 (21%) had other pelvic recurrences, and 1 (4%) had inguinal recurrence.
  • CONCLUSIONS: Trials of more aggressive and innovative locoregional and systemic therapies are warranted in high-risk patients, based on their T and N stages.
  • The majority of locoregional failures involve the anus and rectum, whereas inguinal recurrences occur rarely.
  • [MeSH-major] Anus Neoplasms / mortality. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant / mortality. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / prevention & control. Radiotherapy, Adjuvant / mortality

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17379452.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Karandikar SS, Borley A, Crosby T, Williams G, Reynolds S, Radcliffe AG: A five-year audit of anal cancer in Wales. Colorectal Dis; 2006 May;8(4):266-72
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A five-year audit of anal cancer in Wales.
  • OBJECTIVES: A retrospective audit has been undertaken of Squamous (epidermoid) type of anal cancer diagnosed and treated in the principality of Wales over a five-year period (1995-99) with follow-up until 2005.
  • Twenty-six anal cancers were diagnosed per year in the region.
  • Ten percent had documented perianal Human Papilloma Virus related disease.
  • CONCLUSIONS: This is a unique regional audit of anal cancer.
  • This study concurs that Human Papilloma Virus appears to predispose to Squamous anal cancer.
  • As recommended by NICE all patients should be referred to a multidisciplinary anal cancer team, which can provide individual treatment plans.
  • Increased specialization could mean specialist regional MDTs for anal cancer.
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Medical Audit. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome. Wales / epidemiology

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630228.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


60. Nadal SR, Calore EE, Nadal LR, Horta SH, Manzione CR: [Anal cytology for screening of pre-neoplasic lesions]. Rev Assoc Med Bras (1992); 2007 Mar-Apr;53(2):147-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cytology for screening of pre-neoplasic lesions].
  • [Transliterated title] Citologia anal para rastreamento de lesões pré-neoplásicas.
  • BACKGROUND: High grade intra-epithelial neoplasias (HAIN) are probable precursors of anal carcinoma, with association to high-risk types of Human Papillomavirus (HPV).
  • The aim of this study was to evaluate if anal cytology, with a cytobrush, could be useful to screen clinic and pre-clinic lesions provoked by HPV.
  • METHODS: Brushes were used to obtain smears from the anal canal of 102 HIV-positive patients with proctologic complaints.
  • HPV infection was denied by 33 patients, 14 had treated anal warts in the past, 28 had condylomas in the anal verge, seven had internal clinical lesions and 20 had both internal and external condylomas.
  • One patient with HAIN, without a history of HPV infection in the past, presented an anal canal ulcer which at biopsy was diagnosed as invasive squamous-cell carcinoma.
  • CONCLUSION: Results suggest that cytology could be used to diagnose anal cancer precursors.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma in Situ / pathology. HIV Infections / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Adult. Female. Humans. Male. Mass Screening. Neoplasm Staging. Prospective Studies. Sensitivity and Specificity. Warts / pathology. Warts / virology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17568919.001).
  • [ISSN] 0104-4230
  • [Journal-full-title] Revista da Associação Médica Brasileira (1992)
  • [ISO-abbreviation] Rev Assoc Med Bras (1992)
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


61. Ishiyama S, Inoue S, Kobayashi K, Sano Y, Kushida N, Yamazaki Y, Yanaga K: Implantation of rectal cancer in an anal fistula: report of a case. Surg Today; 2006;36(8):747-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implantation of rectal cancer in an anal fistula: report of a case.
  • A 53-year-old man who had had an anal fistula for 20 years was admitted to our hospital with a large intestinal obstruction.
  • Barium enema and colonoscopy confirmed advanced rectal cancer and we palpated a soft tumor, 3 cm in diameter, with inflammatory induration on the right side of the rectum.
  • After draining a perianal abscess caused by the anal fistula, we performed low anterior resection.
  • Histological examination of the perianal necrotic tissue obtained during resection of the perianal tumor encompassing the anal fistula revealed adenocarcinoma.
  • Since the histology of the perianal lesion was identical to that of the rectal cancer, a diagnosis of cancer implantation rather than carcinoma originating in the anal fistula was entertained.
  • Although the recurrence of rectal cancer by mucosal implantation is not uncommon, the coincidental implantation of rectal cancer in an anal fistula is extremely rare.
  • [MeSH-major] Adenocarcinoma / pathology. Anus Neoplasms / pathology. Neoplasm Seeding. Rectal Fistula / complications. Rectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1955 Jul-Aug;8(4):831-8 [13240668.001]
  • [Cites] Dis Colon Rectum. 2003 Jun;46(6):835-6 [12794588.001]
  • [Cites] Acta Chir Belg. 2002 Jun;102(3):212-3 [12136546.001]
  • [Cites] Aust N Z J Surg. 1965 Feb;34:178-87 [14271060.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):602 [4027530.001]
  • [Cites] Surgery. 1954 Jul;36(1):136-9 [13178955.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):664-5 [6478153.001]
  • [Cites] J R Soc Med. 1992 Jun;85(6):361 [1625275.001]
  • [Cites] Surg Today. 2001;31(12):1094-6 [11827191.001]
  • (PMID = 16865523.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


62. Kim DW, Lim SB, Kim DY, Kim TH, Jung KH, Kim DH, Chang HJ, Sohn DK, Hong CW, Choi HS, Jeong SY, Park JG: Pre-operative chemo-radiotherapy improves the sphincter preservation rate in patients with rectal cancer located within 3 cm of the anal verge. Eur J Surg Oncol; 2006 Mar;32(2):162-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-operative chemo-radiotherapy improves the sphincter preservation rate in patients with rectal cancer located within 3 cm of the anal verge.
  • AIMS: To evaluate whether pre-operative chemo-radiotherapy (CRT) improves the sphincter preservation rate for distal rectal cancers within 3 cm of the anal verge.
  • METHODS: Between January 2001 and December 2004, 49 patients underwent surgery with or without pre-operative CRT for primary rectal adenocarcinoma within 3 cm of the anal verge.
  • RESULTS: Of 49 patients with rectal tumours within 3 cm of the anal verge, 31 underwent pre-operative CRT followed by surgery (CRT group), and 18 underwent surgery alone (non-CRT group).
  • The factors most influencing sphincter preservation were reduction in tumour size (p=0.005) and downstaging (p=0.001) following pre-operative CRT.
  • CONCLUSION: We could observe that sphincter preservation was improved in CRT group with statistical significance when compared to non-CRT group in our study patients with rectal cancer within 3 cm of the anal verge.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Anal Canal / drug effects. Anal Canal / radiation effects. Neoadjuvant Therapy. Rectal Neoplasms / pathology. Rectal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Capecitabine. Chemotherapy, Adjuvant. Combined Modality Therapy. Confounding Factors (Epidemiology). Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Digestive System Surgical Procedures. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16289718.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


63. Zuo ZG, Song HY, Li J, Xu C, Zhou ZH, Ni SC, Chen SQ: [Clinical application of intersphincteric resection in the anal-preserving operation for ultra-low rectal carcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Dec;31(12):941-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical application of intersphincteric resection in the anal-preserving operation for ultra-low rectal carcinoma].
  • OBJECTIVE: To investigate the clinical application of intersphincter resection (ISR) combined with total mesorectal excision (TME) and colon-anal anastomosis in the treatment for ultra-low rectal carcinoma.
  • METHODS: To review and analyze retrospectively the data of 34 patients with ultra-low rectal carcinoma (without external anal sphincter involvement) who received treatment of ISR, TME and colon-anal anastomosis.
  • RESULTS: Partial resection of internal sphincter was performed in the patients with a distal edge of the tumor greater than or equal to 2 cm from the dentate line.
  • Reconstruction of digestive tract was done by manual colon-anal anastomosis.
  • The average distance from distal excised margin to the tumor was 2.3 (1.8 - 3.2) cm among 34 patients.
  • The pathological types were as follows: 28 cases of adenocarcinoma (11 were well differentiated, 17 moderately differentiated), 1 case of papillary carcinoma and 5 cases of villous adenoma with malignant change.
  • CONCLUSION: With strictly grasping indications, radical resection can be attained and anal sphincter preserved by ISR combined with TME and colon-anal anastomosis.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Rectal Neoplasms / surgery. Rectum / surgery
  • [MeSH-minor] Adenoma, Villous / pathology. Adenoma, Villous / surgery. Adult. Aged. Aged, 80 and over. Anastomosis, Surgical. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Surgical Wound Dehiscence / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20193339.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


64. Homsi J, Garrett C: Melanoma of the anal canal: a case series. Dis Colon Rectum; 2007 Jul;50(7):1004-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma of the anal canal: a case series.
  • PURPOSE: Anal melanoma is an uncommon and aggressive cancer.
  • Different surgical modalities have been used in managing the disease with no clear evidence to favor one approach over another.
  • METHODS: The medical records of patients with anal melanoma treated at the H.
  • Published anal melanoma studies, including more than ten patients with outcome data, also were reviewed.
  • RESULTS: Twelve patients were identified (8 percent of all cancer of the anal canal).
  • Four patients had nodal involvement, and one had bone metastases at the time of diagnosis.
  • Five of the 11 patients without metastatic disease relapsed or died within the first year of diagnosis (4 had local excision and 1 had abdominoperineal resection).
  • CONCLUSIONS: Anorectal melanoma is a rare and challenging disease.
  • In the absence of strong survival benefit of abdominoperineal resection in managing the nonmetastatic form of the disease, it is reasonable to consider local excision as the initial treatment of choice.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Digestive System Surgical Procedures / methods. Melanoma. Rectal Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prevalence. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17468984.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


65. Goldstone SE, Kawalek AZ, Huyett JW: Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions. Dis Colon Rectum; 2005 May;48(5):1042-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infrared coagulator: a useful tool for treating anal squamous intraepithelial lesions.
  • PURPOSE: The incidence of invasive anal squamous carcinoma in men who have sex with men is rising, particularly in those with human immunodeficiency virus.
  • This is not possible in the anus, where treatment is often surgical and is accompanied by significant pain and morbidity.
  • Better office-based techniques to treat anal high-grade squamous intraepithelial lesions are needed.
  • Follow-up consisted of anal cytology with high-resolution anoscopy and biopsy of suspicious areas every three to six months.
  • Patients with circumferential or bulky disease were treated in the operating room and were excluded from the study.
  • No patient developed squamous-cell carcinoma, had a serious adverse event, or developed anal stenosis.
  • CONCLUSIONS: The infrared coagulator is a safe, office-based modality for treating anal high-grade squamous intraepithelial lesion in human immunodeficiency virus-positive men who have sex with men.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. HIV Seropositivity. Infrared Rays / therapeutic use. Light Coagulation / methods. Precancerous Conditions / surgery
  • [MeSH-minor] Adult. Chi-Square Distribution. Homosexuality, Male. Humans. Male. Middle Aged. Neoplasm Invasiveness. Proportional Hazards Models. Retrospective Studies. Treatment Outcome


66. Berry JM, Palefsky JM, Jay N, Cheng SC, Darragh TM, Chin-Hong PV: Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia. Dis Colon Rectum; 2009 Feb;52(2):239-47
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Performance characteristics of anal cytology and human papillomavirus testing in patients with high-resolution anoscopy-guided biopsy of high-grade anal intraepithelial neoplasia.
  • PURPOSE: High-resolution anoscopy is colposcopy of the anus after applying 3 percent acetic acid.
  • High-resolution anoscopy with biopsy was used as the standard for detecting high-grade anal neoplasia and was compared to detection of high-grade anal neoplasia by anal cytology, human papillomavirus testing, or the combination.
  • A specimen was taken for anal cytology and human papillomavirus testing, followed by high-resolution anoscopy with biopsy of any lesions.
  • RESULTS: Ninety-one percent of HIV-positive and 57 percent of HIV-negative MSM had anal human papillomavirus infection.
  • In HIV-positive men the sensitivity of abnormal cytology to detect high-grade anal neoplasia was 87 percent, and in HIV-negative MSM it was 55 percent.
  • Among HIV-negative men, 9 of 20 cases of high-grade anal neoplasia would have been missed because cytology was negative, but the addition of human papillomavirus positivity increased sensitivity for the combination to 90 percent.
  • CONCLUSIONS: Sensitivity and specificity of anal cytology and human papillomavirus testing are different in HIV-positive and HIV-negative MSM for detecting high-grade anal neoplasia when patients have high-resolution anoscopy-guided biopsy of lesions.
  • High-resolution anoscopy is an effective tool for diagnosing high-grade anal neoplasia.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / diagnosis. Carcinoma in Situ / diagnosis. Endoscopy, Gastrointestinal. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis
  • [MeSH-minor] Adult. Aged. Anus Diseases / diagnosis. Anus Diseases / virology. Biopsy. Cytodiagnosis. HIV Seronegativity. HIV Seropositivity / complications. Homosexuality. Humans. Male. Middle Aged. Polymerase Chain Reaction. Precancerous Conditions / diagnosis. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19279418.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5 M01-RR-00079; United States / NIAID NIH HHS / AI / K23 AI054157; United States / NIAID NIH HHS / AI / R01 CA/AI 88739; United States / NCI NIH HHS / CA / R01 CA54053; United States / NCRR NIH HHS / RR / UL1 RR024131-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. Poggi MM, Suh WW, Saltz L, Konski AA, Mohiuddin M, Herman J, Johnstone PA: ACR Appropriateness Criteria on treatment of anal cancer. J Am Coll Radiol; 2007 Jul;4(7):448-56
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ACR Appropriateness Criteria on treatment of anal cancer.
  • Anal cancer is a relatively rare neoplasm, accounting for roughly 4,500 cases per year.
  • The evolution of the definitive treatment of anal cancer from a surgical to a nonsurgical approach, however, has been viewed as a model disease site in a larger paradigm shift in medicine.
  • Organ preservation, in this case a functional anal sphincter, and durable cure are obtainable goals.
  • To this end, anal cancer is a disease best treated primarily with chemoradiation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Mitomycin / therapeutic use. Neoplasm Staging. Predictive Value of Tests

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601586.001).
  • [ISSN] 1558-349X
  • [Journal-full-title] Journal of the American College of Radiology : JACR
  • [ISO-abbreviation] J Am Coll Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


68. Lefevre JH, Parc Y, Kernéis S, Shields C, Touboul E, Chaouat M, Tiret E: Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing. Ann Surg; 2009 Nov;250(5):707-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing.
  • OBJECTIVES: To evaluate the results of a vertical rectus abdominis myocutaneus (VRAM) flap after abdomino-perineal resection (APR) for anal cancer (AC).
  • Indications for APR were recurrence of AC (n = 46), persistence of disease (n = 41), and contraindication to radiotherapy (n = 8).
  • Five-year overall and disease-free survival did not differ between the 2 groups (58.1% vs. 54.5%; P = 0.6756; 41.1% vs. 48.9%; P = 0.2756).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Postoperative Complications. Surgical Flaps. Wound Healing
  • [MeSH-minor] Digestive System Surgical Procedures. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Perineum / surgery. Rectus Abdominis. Survival Rate

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801930.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML: High resolution anoscopy in the planned staged treatment of anal squamous intraepithelial lesions in HIV-negative patients. J Gastrointest Surg; 2007 Nov;11(11):1410-5; discussion 1415-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High resolution anoscopy in the planned staged treatment of anal squamous intraepithelial lesions in HIV-negative patients.
  • Anal dysplasia (low-grade squamous intraepithelial lesions, LSIL; high-grade squamous intraepithelial lesions, HSIL) is a challenging disease for the surgeon.
  • We reviewed 42 patients that underwent high-resolution anoscopy (HRA)-targeted surgical therapy of anal dysplasia in the past 10 years.
  • Patients were followed up in the Anal Neoplasia Clinic with physical examination, cytology, HRA, and biopsy if indicated.
  • Patients with disease amenable to local therapy were treated with office-based HRA-directed therapies.
  • HSIL was present in 33, with four undergoing planned staged treatment due to circumferential disease.
  • HRA-targeted surgical therapy coupled with surveillance and re-treatment with office-based therapies offered an effective method in controlling anal dysplasia in the immunocompetent patient.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / surgery

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):36-40 [16283561.001]
  • [Cites] Dis Colon Rectum. 2007 May;50(5):565-75 [17380365.001]
  • [Cites] Dis Colon Rectum. 1987 Oct;30(10):782-5 [3652891.001]
  • [Cites] Dis Colon Rectum. 2006 Jan;49(1):126 [16222485.001]
  • [Cites] Arch Surg. 2004 Mar;139(3):259-61 [15006881.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] Dis Colon Rectum. 2001 May;44(5):690-8 [11357031.001]
  • [Cites] Br J Surg. 1999 Aug;86(8):1063-6 [10460644.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):355-73 [15137962.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):912-8 [9269807.001]
  • [Cites] Dis Colon Rectum. 1997 Aug;40(8):919-28 [9269808.001]
  • [Cites] ANZ J Surg. 2006 Aug;76(8):715-7 [16916390.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1133-6 [16044425.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1286-93 [9369101.001]
  • (PMID = 17710507.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Donigan M, Norcross LS, Aversa J, Colon J, Smith J, Madero-Visbal R, Li S, McCollum N, Ferrara A, Gallagher JT, Baker CH: Novel murine model for colon cancer: non-operative trans-anal rectal injection. J Surg Res; 2009 Jun 15;154(2):299-303

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel murine model for colon cancer: non-operative trans-anal rectal injection.
  • Different magnifications (10x versus 100x) were used for injection, and primary tumor growth and metastatic disease were studied.
  • RESULTS: In the initial study, 3/7 mice injected using 10x magnifications had notable, large tumor originating from the rectal wall, and histology revealed that all excised tumors were poorly differentiated adenocarcinoma.
  • In the second study, 8/10 mice injected using 100x magnifications had notable tumor originating from the rectal well, and 4/8 mice had abnormal lung tissue with pathological evidence of hemorrhagic pulmonary edema.
  • The use of 10x magnification resulted in 43% tumor take.
  • In sharp contrast, 80% tumor take was observed with 100x magnification.
  • The overall success of tumor take was 65% using the trans-anal rectal injection model.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Disease Models, Animal. Mice, Inbred BALB C. Neoplasm Transplantation / methods. Rectum / pathology
  • [MeSH-minor] Anal Canal. Animals. Cell Differentiation. Cell Line, Tumor. Injections / methods. Lung / pathology. Lung Neoplasms / secondary. Mice. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19101690.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Spugnini EP, Dotsinsky I, Mudrov N, Bufalini M, Giannini G, Citro G, Feroce F, Baldi A: Adjuvant electrochemotherapy for incompletely excised anal sac carcinoma in a dog. In Vivo; 2008 Jan-Feb;22(1):47-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant electrochemotherapy for incompletely excised anal sac carcinoma in a dog.
  • Canine anal sac gland carcinoma (ASGC) is a frequently described neoplasm that is highly aggressive and can frequently lead to metastatic spread.
  • In this paper, we describe the successful treatment of an incompletely excised ASGC by using cisplatin selectively driven within the tumor cells by trains of biphasic pulses.
  • [MeSH-major] Anal Gland Neoplasms / drug therapy. Anal Sacs / drug effects. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Dog Diseases / drug therapy. Electrochemotherapy
  • [MeSH-minor] Animals. Combined Modality Therapy. Disease-Free Survival. Dogs. Male. Remission Induction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396781.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


72. Handisurya A, Rieger A, Bago-Horvath Z, Schellenbacher C, Bankier A, Salat A, Stingl G, Kirnbauer R: Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient. Sex Transm Infect; 2009 Aug;85(4):261-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient.
  • BACKGROUND: Buschke-Löwenstein tumour (BLT) of the anogenitalia is a locally invasive, destructively growing verrucous carcinoma that does not metastasise.
  • Histologically BLT resembles benign condylomata acuminata.
  • Nevertheless, the tumour grows relentlessly and may rarely progress into squamous cell cancer (SCC).
  • RESULTS: A human immunodeficiency virus (HIV)-infected immunosuppressed patient developed (peri)anal warts accompanied by recurrent abscesses and fistulae.
  • Six months later, the tumour had progressed into an ulcerated SCC that destroyed the rectum and perineum, with metastases to the inguinal lymph nodes.
  • Whereas highly active antiretroviral therapy (HAART) effectively suppressed HIV replication, radiochemotherapy plus anti-EGFR antibody did not halt tumour progression, and the patient died from tumour-cachexia.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / secondary. HIV Infections / complications. Immunocompromised Host
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / virology. Anti-HIV Agents / therapeutic use. Cachexia / etiology. Fatal Outcome. Groin. HIV Seropositivity / drug therapy. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness


73. Quintás-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P: Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol; 2008 Dec;5(12):737-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
  • INVESTIGATIONS: Physical examination; excisional biopsy; CT scan of the chest, abdomen and pelvis; lung biopsy; blood tests; tumor immunohistochemistry for KIT, vascular endothelial growth factor platelet-derived growth factor receptor alpha and beta, and mismatch-repair proteins MLH1, MSH2, and MSH6; and KIT and BRAF tumor genotyping.
  • DIAGNOSIS: Stage IV M1b metastatic anal mucosal melanoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / therapy. Benzenesulfonates / therapeutic use. Melanoma / therapy. Pyridines / therapeutic use
  • [MeSH-minor] Aged. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Humans. Male. Neoplasm Staging. Niacinamide / analogs & derivatives. Phenylurea Compounds. Proto-Oncogene Proteins c-kit / metabolism. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936790.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


74. Khanfir K, Ozsahin M, Bieri S, Cavuto C, Mirimanoff RO, Zouhair A: Patterns of failure and outcome in patients with carcinoma of the anal margin. Ann Surg Oncol; 2008 Apr;15(4):1092-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure and outcome in patients with carcinoma of the anal margin.
  • BACKGROUND: To evaluate the outcome of patients with carcinoma of anal margin in terms of recurrence, survival, and radiation toxicity.
  • METHODS: A series of 45 consecutive patients, with anal margin carcinoma treated between 1983 and 2006 with curative intent at two institutions, was retrospectively analyzed.
  • The 5-year disease-specific survival (DSS) and overall survival (OS) rates were respectively 86% (95% CI, 72-99%) and 55% (95% CI, 44-66%).
  • The overall anal conservation rate was 80% for the whole series.
  • There was no significant association between local recurrence and patient age, histological grade, tumor size, T stage, overall treatment time, RT dose, or chemotherapy.
  • CONCLUSIONS: We conclude that definitive RT and/or BT yield a good local control and disease-specific survival comparable with published data.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Failure. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18231838.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Zagar TM, Willett CG, Czito BG: Intensity-modulated radiation therapy for anal cancer: toxicity versus outcomes. Oncology (Williston Park); 2010 Aug;24(9):815-23, 828
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation therapy for anal cancer: toxicity versus outcomes.
  • The treatment of cancer of the anal canal has changed significantly over the past several decades.
  • Although the abdominoperineal resection (APR) was the historical standard of care, a therapeutic paradigm shift occurred with the seminal work of Nigro, who reported that anal canal cancer could be treated with definitive chemoradiation, with APR reserved for salvage therapy only.
  • This remains an attractive approach for patients and physicians alike and the standard of care in this disease.
  • With the advent of intensity-modulated radiation therapy (IMRT), many oncologists are beginning to utilize this technology in the treatment of anal cancer in order to decrease these toxicities while maintaining similar treatment efficacy.
  • This article reviews the relevant literature leading up to the modern treatment of anal canal cancer, and discusses IMRT-related toxicity and disease-related outcomes in the context of outcomes of conventionally treated anal cancer.
  • [MeSH-major] Anus Neoplasms. Radiotherapy, Intensity-Modulated / adverse effects. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Anal Canal / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Humans. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2010 Aug;24(9):828, 830-1 [20923036.001]
  • (PMID = 20923035.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


76. Caricato M, Ausania F, Marangi GF, Cipollone I, Flammia G, Persichetti P, Trodella L, Coppola R: Surgical treatment of locally advanced anal cancer after male-to-female sex reassignment surgery. World J Gastroenterol; 2009 Jun 21;15(23):2918-9
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of locally advanced anal cancer after male-to-female sex reassignment surgery.
  • We present a case of a transsexual patient who underwent a partial pelvectomy and genital reconstruction for anal cancer after chemoradiation.
  • This is the first case in literature reporting on the occurrence of anal cancer after male-to-female sex reassignment surgery.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / surgery. Reconstructive Surgical Procedures. Transsexualism / surgery

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Plast Surg. 2007 Aug;59(2):168-72 [17667411.001]
  • [Cites] Plast Reconstr Surg. 1980 Sep;66(3):401-6 [6999512.001]
  • (PMID = 19533817.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2699013
  •  go-up   go-down


77. Renehan AG, Saunders MP, Schofield PF, O'Dwyer ST: Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg; 2005 May;92(5):605-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer.
  • BACKGROUND: Salvage surgery for anal cancer is usually reserved for local disease failure, but issues relating to the prediction of local failure and surgical outcome are ill defined.
  • METHODS: Between 1988 and 2000, 254 patients with non-metastatic anal epidermoid carcinoma were treated at a regional cancer centre with radiotherapy (n = 127) or chemoradiotherapy (n = 127).
  • RESULTS: There were 99 local disease failures (39.0 per cent), all but five occurring within 3 years of initial treatment.
  • Increasing age (P < 0.001, Cox model), total radiation dose (P = 0.004) and tumour stage (P = 0.010) were independent predictors of local failure.
  • The overall 3- and 5-year survival rates after local disease failure were 46 and 29 per cent; the corresponding rates after salvage surgery (73 patients) were 55 and 40 per cent.
  • Of 52 patients treated before the routine consideration of primary plastic reconstruction, delayed perineal wound healing occurred in 22 (42 per cent).
  • CONCLUSION: In the management of anal cancer, local disease failure is a major clinical problem requiring early detection followed by radical surgery, often accompanied by plastic reconstruction.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colostomy / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm, Residual. Postoperative Complications / etiology. Proportional Hazards Models. Prospective Studies. Survival Analysis. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 15739215.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


78. Zucchini C, Concu M, Martini F, Morelli C, Salfi N, Carinci P, Tognon M, Caramelli E: FHIT oncosuppressor gene expression profile in human anal cancers. Int J Biol Markers; 2007 Jan-Mar;22(1):39-42
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FHIT oncosuppressor gene expression profile in human anal cancers.
  • The FHIT gene, a member of the histidine triad gene family, is a tumor suppressor gene exhibiting deletions in the majority of human cancers.
  • Little is known about the molecular mechanisms involved in malignant transformation of the lining cells of the anus.
  • FHIT expression was comparatively analyzed at the mRNA level, by RT-PCR, in squamous anal cancers, normal anal tissue and peripheral blood samples. cDNA analyses showed variability in FHIT transcripts, without apparent effects on the predicted amino acid sequence.
  • Our data indicate that the FHIT mRNA detected in anal cancers and in normal samples is heterogeneous.
  • Immunohistochemical data suggest that the Fhit protein is expressed only in a fraction of the tumor cells, while it is strongly expressed in the epithelial cells of glands of the normal anal mucosa.
  • The absence or poor expression of the Fhit protein in anal cancers suggests a role for this tumor suppressor gene product, as a risk factor, in the onset of this human cancer, as reported before for other human gastrointestinal tumors.
  • [MeSH-major] Acid Anhydride Hydrolases / biosynthesis. Anus Neoplasms / metabolism. Neoplasm Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17393360.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


79. Emms SG: Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy. Aust Vet J; 2005 Jun;83(6):340-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy.
  • A retrospective study of anal sac tumours without pulmonary metastases, from the author's clinical records for the period July 1989 to July 2002, was conducted to establish the response to treatment with surgery and melphalan chemotherapy.
  • Of 21 dogs with tumours of the anal sacs 19 had apocrine gland adenocarcinomas of anal sac origin, one had a benign papillary cystadenoma and another had a malignant melanoma.
  • Two of the 19 dogs had bilateral anal sac adenocarcinomas.
  • Ten of the 19 dogs with apocrine gland adenocarcinomas of anal sac origin had sublumbar lymphadenopathy.
  • Fourteen dogs with apocrine gland adenocarcinomas of anal sac origin were treated by surgical cytoreduction and chemotherapy with melphalan.
  • Cytoreduction was by local excision of the anal sac in all 14 dogs and concurrent removal of the sublumbar retroperitoneal lymph nodes in the seven dogs with regional lymph node metastases.
  • The median survival time of dogs with sublumbar nodal metastasis was 20 months and for dogs with tumour localised to the anal sac the median survival time was 29.3 months.
  • This study suggests there is a role for melphalan in the treatment of dogs with anal sac adenocarcinoma when combined with cytoreductive surgery, with treatment survival times and the local recurrence rate of the primary tumour comparing favourably with previously published treatment regimes.
  • [MeSH-major] Anal Gland Neoplasms / epidemiology. Anal Sacs. Dog Diseases / epidemiology
  • [MeSH-minor] Adenocarcinoma / veterinary. Animals. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Combined Modality Therapy. Cystadenoma, Papillary / veterinary. Dogs. Female. Male. Melanoma / veterinary. Neoplasm Metastasis. Records as Topic / veterinary. Retrospective Studies. Survival Analysis. Victoria / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986909.001).
  • [ISSN] 0005-0423
  • [Journal-full-title] Australian veterinary journal
  • [ISO-abbreviation] Aust. Vet. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


80. Shoieb AM, Hanshaw DM: Anal sac gland carcinoma in 64 cats in the United kingdom (1995-2007). Vet Pathol; 2009 Jul;46(4):677-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal sac gland carcinoma in 64 cats in the United kingdom (1995-2007).
  • A retrospective study was performed to characterize 64 cases of anal sac gland carcinoma (ASGC) in cats.
  • Apocrine gland origin was confirmed in a subset of these tumors by immunohistochemistry and the use of the glandular cytokeratin antibody (CAM 5.2).
  • Anal sac gland carcinoma accounted for 0.5% of all feline skin neoplasms.
  • Fifty-two (81.1%) of the 64 tumors were in Domestic Shorthair cats, 5 (7.8%) in Siamese, 3 (4.8%) in Domestic Longhair, 2 (3.1%) in Burmese, and 1 (1.6%) each in a Birman and a Persian cat.
  • More than three quarters of the affected cats for which postsurgical outcome was known were euthanatized or died as a direct consequence of the neoplasm, with a median survival of 3 months.
  • [MeSH-major] Anal Gland Neoplasms / epidemiology. Anal Gland Neoplasms / pathology. Anal Sacs / pathology. Cat Diseases / epidemiology. Cat Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276061.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


81. Scholefield JH, Castle MT, Watson NF: Malignant transformation of high-grade anal intraepithelial neoplasia. Br J Surg; 2005 Sep;92(9):1133-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of high-grade anal intraepithelial neoplasia.
  • BACKGROUND: The natural history of anal intraepithelial neoplasia (AIN) is uncertain.
  • Diagnosis was by full-thickness biopsy and histopathological examination.
  • Six patients were systemically immunosuppressed at diagnosis, all of whom had multifocal perianal lesions.
  • Three immunosuppressed patients developed invasive anal squamous carcinoma during follow-up.
  • By contrast, no invasive carcinomas were identified among immunocompetent patients with either localized or multifocal perianal disease.
  • CONCLUSION: AIN III appears to have a relatively low potential for malignant transformation in the immunocompetent patient.
  • However, immunosuppressed patients are more likely to have extensive AIN III and a greater risk of malignant change.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma in Situ / pathology. Cell Transformation, Neoplastic / pathology
  • [MeSH-minor] Adult. Carcinoma, Squamous Cell / pathology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local. Prospective Studies

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 British Journal of Surgery Society Ltd.
  • (PMID = 16044425.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


82. Lee J, Corman M: Recurrence of anal adenocarcinoma after local excision and adjuvant chemoradiation therapy: report of a case and review of the literature. J Gastrointest Surg; 2009 Jan;13(1):150-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of anal adenocarcinoma after local excision and adjuvant chemoradiation therapy: report of a case and review of the literature.
  • INTRODUCTION: Tumors arising from the anal canal are rare, comprising 1.5% of all gastrointestinal tumors in the USA.
  • The vast majority of these anal cancers are epidermoid (cloacogenic/basaloid and squamous cell carcinomas), while adenocarcinomas reportedly occur 5% to 19% of the time.
  • Because of its rarity, reports about anal adenocarcinoma are limited to small retrospective studies and case reports.
  • CASE PRESENTATION: We describe a case of recurrent anal adenocarcinoma after conservative management with local excision and adjuvant chemoradiation therapy.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Agents / therapeutic use. Anus Neoplasms / pathology. Anus Neoplasms / therapy. Colectomy / methods
  • [MeSH-minor] Adult. Biopsy. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1996 Dec;49(12):1009-11 [9038740.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):669-78 [12573754.001]
  • [Cites] Zhonghua Wei Chang Wai Ke Za Zhi. 2006 Sep;9(5):402-4 [17043960.001]
  • [Cites] Am J Surg. 1995 Feb;169(2):233-7 [7840386.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1320-4 [14530668.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1274-83 [12873671.001]
  • [Cites] Semin Surg Oncol. 1994 May-Jun;10(3):235-40 [8085101.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1199-205 [10613313.001]
  • [Cites] Histopathology. 1994 Dec;25(6):507-16 [7698728.001]
  • [Cites] Mod Pathol. 1991 Jan;4(1):58-61 [1850518.001]
  • [Cites] Cancer. 1997 Aug 15;80(4):805-15 [9264365.001]
  • (PMID = 18810561.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


83. Nahas SC, Nahas CS, Silva Filho EV, Levi JE, Atui FC, Marques CF: Perianal squamous cell carcinoma with high-grade anal intraepithelial neoplasia in an HIV-positive patient using highly active antiretroviral therapy: case report. Sao Paulo Med J; 2007 Sep 6;125(5):292-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perianal squamous cell carcinoma with high-grade anal intraepithelial neoplasia in an HIV-positive patient using highly active antiretroviral therapy: case report.
  • CONTEXT: Highly active antiretroviral therapy (HAART) has turned human immunodeficiency virus (HIV) infection into a chronic condition, and this has led to increased incidence of anal dysplasia among HIV-positive patients.
  • Routine anal evaluation including the anal canal and perianal area is recommended for this population, especially for patients infected by oncogenic human papillomavirus (HPV) types.
  • CASE REPORT: A 54-year-old homosexual HIV-positive man presented with a six-year history of recurrent perianal and anal warts.
  • He presented some condylomatous spreading lesions occupying part of the anal canal and the perianal skin, and also a well-demarcated slightly painful perianal plaque of dimensions 1.0 x 1.0 cm.
  • Both anal canal Pap smears and biopsies guided by high-resolution anoscopy revealed high-grade squamous intraepithelial lesion.
  • HPV DNA testing of the anus detected the presence of HPV-16 type.
  • The patient showed pathological evidence of recurrent anal and perianal high-grade squamous intraepithelial lesions at the sixth-month follow-up and required further ablation of those lesions.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / adverse effects. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. HIV Seropositivity / drug therapy. Human papillomavirus 16 / isolation & purification. Papillomavirus Infections / pathology
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / virology. DNA, Viral / analysis. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis


84. Wexler A, Berson AM, Goldstone SE, Waltzman R, Penzer J, Maisonet OG, McDermott B, Rescigno J: Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum; 2008 Jan;51(1):73-81
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy.
  • INTRODUCTION: The incidence of invasive anal squamous-cell carcinoma in patients with HIV is increasing.
  • We report the outcome after combined chemoradiotherapy for anal squamous-cell carcinoma in HIV-infected individuals.
  • METHODS: Thirty-two HIV-positive patients treated at the St. Vincent's Cancer Care Center for anal squamous-cell carcinoma from 1997 through mid 2005 were reviewed retrospectively.
  • Overall survival, anal cancer-specific survival, local recurrence, and toxicity were assessed.
  • Five-year locoregional relapse, anal cancer-specific survival, and overall survival were 16 , 75, and 65 percent, respectively.
  • In multivariate analysis, locoregional recurrence, cancer-specific survival, and overall survival were all significantly associated with tumor size.
  • CONCLUSIONS: Outcome after chemoradiotherapy for HIV-related anal squamous-cell carcinoma in the era of highly active antiretroviral therapy is comparable to outcome in patients without HIV.
  • Earlier diagnosis and risk-adapted therapy could lead to improved survival and decreased treatment-related morbidity.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / pathology. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. HIV Seropositivity / complications
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Proportional Hazards Models. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome


85. Hobson HP, Brown MR, Rogers KS: Surgery of metastatic anal sac adenocarcinoma in five dogs. Vet Surg; 2006 Apr;35(3):267-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery of metastatic anal sac adenocarcinoma in five dogs.
  • OBJECTIVE: To identify survival and morbidity information after surgery for metastases from apocrine gland anal sac adenocarcinomas (AGACA).
  • CONCLUSION: Dogs with anal sac adenocarcinoma metastases to the iliac lymph nodes can experience long-term survival after surgical excision of the metastatic lesion.
  • CLINICAL RELEVANCE: Lymphadenectomy may afford long-term survival to patients with metastatic anal sac adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / veterinary. Anal Gland Neoplasms / surgery. Anal Sacs. Dog Diseases / surgery
  • [MeSH-minor] Animals. Dogs. Female. Lymph Node Excision / veterinary. Lymphatic Metastasis. Male. Neoplasm Metastasis. Postoperative Complications / veterinary. Records as Topic / veterinary. Retrospective Studies. Survival Analysis. Texas / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Compend Contin Educ Vet. 2008 Feb;30(2):69, 72 [23713167.001]
  • (PMID = 16635006.001).
  • [ISSN] 0161-3499
  • [Journal-full-title] Veterinary surgery : VS
  • [ISO-abbreviation] Vet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Cummings BJ: Current management of anal canal cancer. Semin Oncol; 2005 Dec;32(6 Suppl 9):S123-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of anal canal cancer.
  • Combined-modality therapy consisting of radiation therapy and 5-fluorouracil plus mitomycin remains the standard treatment for localized anal canal cancer, permitting preservation of organ function and achieving high response and survival rates.
  • Metastatic disease is less responsive to chemoradiation treatment.
  • Neoadjuvant and adjuvant strategies are being evaluated, and additional drugs including capecitabine, irinotecan, and oxaliplatin are being assessed in treatment of localized and advanced disease.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Neoplasm Staging. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399449.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


87. Tomimaru Y, Ohue M, Noura S, Tanida T, Miyashiro I, Yano M, Ohigashi H, Sasaki Y, Ishikawa O, Imaoka S: [A case of anal fistula cancer probably developing from intraluminal dissemination of rectal cancer]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1776-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of anal fistula cancer probably developing from intraluminal dissemination of rectal cancer].
  • A 63-year-old man with a history of anal fistula was admitted to our hospital because the anal pain didn't disappear after the operation.
  • On digital examination, a hard mass measuring 3.0 cm in diameter was found at the anal canal.
  • Colonoscopy revealed another rectal cancer at 15 cm from anal verge.
  • Biopsy of the tumor also showed moderately differentiated adenocarcinoma, resembling the anal canal tumor.
  • Because the histological findings of both tumors were nearly identical, we considered that cancer cells from the rectal cancer had been implanted and developed the metastatic tumor in the anal fistula.
  • The patient underwent anterior resection for the rectal cancer, and a local resection for the anal canal cancer.
  • Immunohistochemical staining for Ki-67, p53, Muc2, CD10, CK-7, and CK-20 revealed similar patterns in both tumors.
  • Additionally, genetic analysis for p53, K-ras, and MSI revealed similar patterns in both tumors.
  • We may suggest from these results that cancer cells from the rectal cancer had been implanted and developed the metastatic tumor in the anal canal.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Anus Neoplasms / secondary. Rectal Fistula / complications. Rectal Neoplasms / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Seeding


88. Facy O, Lagoutte N, Jambet S, Radais F, Favre JP, Rat P, Ortega Deballon P: [After low anterior rectal resection, colonic pull-through with delayed colo-anal anastomosis can avoid the need for a diverting ileostomy]. J Chir (Paris); 2009 Oct;146(5):458-63

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [After low anterior rectal resection, colonic pull-through with delayed colo-anal anastomosis can avoid the need for a diverting ileostomy].
  • [Transliterated title] Anastomose colo-anale différée sans stomie de dérivation après résection antérieure basse du rectum.
  • A delayed colo-anal anastomosis has been proposed as a way to avoid diverting stoma after low anterior resection.
  • Rates of parietal and septic complications are low after delayed colo-anal anastomosis and functional results are good.
  • [MeSH-major] Anal Canal / surgery. Colon / surgery. Ileostomy / methods. Rectal Neoplasms / surgery. Rectum / surgery
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical. Female. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Complications. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19833335.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


89. Tajima Y, Ishibashi K, Gonda T, Miyazaki T, Nakada H, Takahashi T, Ishida H: [Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2050-2
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report].
  • We report a case of squamous cell carcinoma of the anal canal which showed complete response following chemoradiotherapy.
  • A 54-year-old woman was diagnosed as having squamous cell carcinoma of the anal canal (T2N0M0 stage II).
  • This case suggests that we should take measures to prevent distant metastases in the treatment of squamous cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonoscopy. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neoplasm Metastasis / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219895.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


90. Hatfield P, Cooper R, Sebag-Montefiore D: Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma. Int J Radiat Oncol Biol Phys; 2008 Feb 1;70(2):419-24
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma.
  • PURPOSE: To report the results of patients with early-stage anal cancer treated using a low-dose, reduced-volume, involved-field chemoradiotherapy protocol.
  • Of the 21 patients, 17 had had lesions that were excised with close (<1 mm) or involved margins, 1 had had microinvasive disease on biopsy, and 3 had had macroscopic tumor <2 cm in diameter (T1).
  • All were considered to have Stage N0 disease radiologically.
  • RESULTS: After a median follow-up of 42 months, only 1 patient (4.7%) had experienced local recurrence and has remained disease free after local excision.
  • CONCLUSION: The results of our study have shown that for patients with anal carcinoma who have residual microscopic or very-small-volume disease, a policy of low-dose, reduced-volume, involved-field chemoradiotherapy produces excellent local control and disease-free survival, with low rates of acute and late toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / methods. Dose Fractionation. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17919842.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


91. Damin DC, Tolfo GC, Rosito MA, Spiro BL, Kliemann LM: Sentinel lymph node in patients with rectal cancer invading the anal canal. Tech Coloproctol; 2010 Jun;14(2):133-9
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node in patients with rectal cancer invading the anal canal.
  • BACKGROUND: To assess the feasibility of the sentinel lymph node procedure in patients with rectal cancer extending to the anal canal.
  • METHODS: Between January 2005 and April 2008, 15 patients with adenocarcinoma of the rectum with direct invasion of the anal canal and no clinical evidence of inguinal involvement were prospectively enrolled in the study.
  • CONCLUSIONS: The standardized procedure was highly effective in sampling inguinal sentinel nodes in very low rectal cancers, allowing the detection of subclinical metastatic disease.
  • Although this technique can be potentially useful for a subgroup of patients with isolated inguinal metastases, it cannot be routinely recommended for patients with rectal tumors invading the anal canal at this moment.
  • [MeSH-major] Adenocarcinoma / secondary. Anal Canal. Inguinal Canal. Rectal Neoplasms / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prospective Studies

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2008 Aug;34(8):890-4 [18178364.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2009 Feb;53(1):3-8 [18337684.001]
  • [Cites] Cancer Radiother. 2003 Nov;7 Suppl 1:85s-90s [15124549.001]
  • [Cites] Eur J Surg Oncol. 2006 Apr;32(3):247-52 [16289647.001]
  • [Cites] Gastroenterol Clin Biol. 2009 May;33(5):446-50 [19264433.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Jun;10(6):811-9 [6429097.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):2058-65 [8364884.001]
  • [Cites] Ann Surg Oncol. 2004 Mar;11(3 Suppl):259S-62S [15023764.001]
  • [Cites] Dis Colon Rectum. 2003 Aug;46(8):1027-9; discussion 1030-1 [12907894.001]
  • [Cites] Strahlenther Onkol. 2009 Apr;185(4):254-9 [19370429.001]
  • [Cites] Colorectal Dis. 2010 Apr;12(4):312-5 [19250258.001]
  • [Cites] Colorectal Dis. 2010 Oct;12(10 Online):e200-5 [19912287.001]
  • [Cites] Dis Colon Rectum. 1999 Nov;42(11):1464-6 [10566535.001]
  • [Cites] Am J Surg. 1994 Sep;168(3):285-7 [8080070.001]
  • [Cites] Surg Gynecol Obstet. 1989 Sep;169(3):238-42 [2672386.001]
  • [Cites] World J Urol. 2009 Apr;27(2):197-203 [18594830.001]
  • [Cites] Scand J Surg. 2002;91(4):336-8 [12558082.001]
  • [Cites] Radiother Oncol. 2001 Oct;61(1):15-22 [11578724.001]
  • [Cites] Br J Clin Pract. 1984 Sep;38(9):324-5 [6477814.001]
  • [Cites] J Surg Oncol. 1999 Mar;70(3):177-80 [10102348.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):741-7 [11597817.001]
  • [Cites] Dis Colon Rectum. 1990 Mar;33(3):212-6 [2311465.001]
  • [Cites] Dis Colon Rectum. 2003 Aug;46(8):1032-7 [12907896.001]
  • (PMID = 20424879.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


92. Vietharsdóttir H, Moeller PH, Jóhannsson J, Jónasson JG: [Anal cancer in Iceland 1987-2003. A population based study]. Laeknabladid; 2006 May;92(5):365-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cancer in Iceland 1987-2003. A population based study].
  • OBJECTIVE: Anal cancer is a rare disease.
  • The aim of this study was to describe anal cancer in Iceland in 1987-2003 with respect to incidence, histologic type, treatment, recurrence rate and survival.
  • MATERIAL AND METHODS: This is a retrospective study in which all malignant anal tumours diagnosed in Iceland in the period 1987-2003 were reviewed with respect to patient outcome.
  • This is a nationwide, population-based study of malignant tumours of the anal region.
  • RESULTS: From 1987-2003 thirty-eight patients were diagnosed with anal cancer, 28 females and 10 males.
  • The average age at diagnosis was 63.4 years.
  • Age standardized incidence rates for anal cancer in Iceland were 0.3 (+/-0.2) of 100.000 males and 0.9 (+/-0.4) of 100.000 females.
  • The remaining histologic types were malignant melanoma (n=3), adenosquamous carcinoma (n=1), adenocarcinoma (n=1), GIST (n=1) and undifferentiated carcinoma (n=2).
  • The duration of symptoms before diagnosis ranged from 2 weeks to 96 months (mean value 3.5 months).
  • The mean value of the time from diagnosis of the primary to the recurrent cancer was 15.6 months (range, 5.9-117).
  • Sixteen patients remain with disease and ten have died of anal cancer.
  • CONCLUSION: Age-standardized incidence for anal cancer in Iceland is similar to other regions.
  • Average age at diagnosis, male-female ratio and prognosis is similar to reports in other studies.
  • The proportion of adenocarcinoma of the anus is lower in Iceland than elsewhere.
  • [MeSH-major] Anus Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Aged. Carcinoma / epidemiology. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Squamous Cell / epidemiology. Defecation. Female. Gastrointestinal Hemorrhage / etiology. Humans. Iceland / epidemiology. Incidence. Male. Melanoma / epidemiology. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pain / etiology. Pruritus / epidemiology. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741319.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


93. Ferenschild FT, Vermaas M, Hofer SO, Verhoef C, Eggermont AM, de Wilt JH: Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer. World J Surg; 2005 Nov;29(11):1452-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer.
  • The primary treatment for anal cancer is chemoradiation (CRT).
  • A major problem of surgery in the anal area is poor healing of the perineal wound.
  • Between 1985 and 2000, 129 patients treated for anal cancer were retrospectively reviewed.
  • Mean age at diagnosis was 59 (range: 41-83) years.
  • In the present study salvage APR in recurrent or persistent anal cancer results in good local control and 5-year overall survival of 30%.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / surgery. Salvage Therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1992 Jun;35(6):574-7; discussion 577-8 [1587176.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1525-9 [9769399.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):114-25 [6326995.001]
  • [Cites] J Gastrointest Surg. 2001 Jul-Aug;5(4):383-7 [11985979.001]
  • [Cites] Surg Gynecol Obstet. 1970 Nov;131(5):953-7 [5471546.001]
  • [Cites] Surg Clin North Am. 2002 Dec;82(6):1233-51 [12516851.001]
  • [Cites] Cancer. 1986 Feb 1;57(3):525-9 [3942984.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):997-1005 [11240240.001]
  • [Cites] Br J Surg. 2003 May;90(5):575-80 [12734865.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1007-13 [11240241.001]
  • [Cites] Plast Reconstr Surg. 1988 Jan;81(1):62-73 [2962215.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]
  • [Cites] Ann Surg Oncol. 1994 Mar;1(2):105-10 [7834434.001]
  • [Cites] Cancer. 1999 Aug 1;86(3):405-9 [10430247.001]
  • [Cites] Clin Plast Surg. 1990 Oct;17(4):705-12 [2249391.001]
  • [Cites] AJR Am J Roentgenol. 1979 Nov;133(5):790-5 [115262.001]
  • [Cites] Dis Colon Rectum. 1989 Sep;32(9):773-7 [2503342.001]
  • [Cites] Proc R Soc Med. 1941 Jan;34(3):139-60 [19992316.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Arch Surg. 2000 Sep;135(9):1090-3; discussion 1094-5 [10982516.001]
  • [Cites] Surg Gynecol Obstet. 1985 Dec;161(6):509-17 [3934775.001]
  • [Cites] Br J Plast Surg. 1984 Jul;37(3):330-50 [6234962.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1425-9 [12390386.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Dis Colon Rectum. 1998 Dec;41(12):1488-93 [9860327.001]
  • (PMID = 16222445.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Grigsby PW: FDG-PET/CT: new horizons in anal cancer. Gastroenterol Clin Biol; 2009 May;33(5):456-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET/CT: new horizons in anal cancer.
  • Anal cancer is an uncommon tumor with an incidence of about one case per 100,000 in most countries.
  • Current treatment guidelines include fluorodeoxyglucose positron emission tomography integrated with computed tomography (FDG-PET/CT) as part of the standard pretreatment workup of patients diagnosed with anal cancer.
  • At diagnosis, FDG-PET/CT is used to evaluate primary tumor size, lymph node status and to evaluate for distant metastases.
  • FDG-PET/CT can also be used for radiation therapy treatment planning by clearly defining sites of metabolically active tumor.
  • This imaging modality can also be used to evaluate sites of recurrent disease.
  • FDG-PET/CT is an imaging modality which greatly affects the management of patients with anal cancer.
  • [MeSH-major] Anus Neoplasms / radiography. Anus Neoplasms / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Humans. Neoplasm Staging

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394179.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


95. Otto SD, Lee L, Buhr HJ, Frericks B, Höcht S, Kroesen AJ: Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging. J Gastrointest Surg; 2009 Jul;13(7):1292-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging anal cancer: prospective comparison of transanal endoscopic ultrasound and magnetic resonance imaging.
  • PURPOSE: The staging of anal cancer is extremely important for therapy and prognosis.
  • The aim of this prospective comparative study is to evaluate whether tumor staging is concordant between these techniques.
  • METHODS: Forty-five anal cancer patients underwent endoscopic ultrasound and magnetic resonance imaging.
  • The two test methods were compared with the kappa concordance index and sensitivity for the initial method of tumor detection was calculated.
  • For six patients who were operated upon because of tumor progression, the results were evaluated against the histological tumor stage.
  • RESULTS: High concordance was found in the assessment of tumor size and nodal status (kappa index 0.63 and 0.77).
  • Endoscopic ultrasound may be superior to magnetic resonance imaging for detection of small superficial tumors.
  • [MeSH-major] Anus Neoplasms / diagnostic imaging. Anus Neoplasms / pathology. Endosonography. Magnetic Resonance Imaging. Neoplasm Staging / methods
  • [MeSH-minor] Adenocarcinoma / diagnostic imaging. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Squamous Cell / diagnostic imaging. Carcinoma, Squamous Cell / pathology. Cohort Studies. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Invasiveness / diagnostic imaging. Neoplasm Invasiveness / pathology. Prospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2008 Jun 14;14 (22):3504-10 [18567078.001]
  • [Cites] Surg Endosc. 2008 Nov;22(11):2412-5 [18622554.001]
  • [Cites] Int J Colorectal Dis. 2000 Nov;15(5-6):282-90 [11151431.001]
  • [Cites] Endoscopy. 1995 Sep;27(7):469-79 [8565885.001]
  • [Cites] Surg Endosc. 2000 Nov;14 (11):1005-9 [11116406.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):895-900 [17352019.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):16-22 [11786758.001]
  • [Cites] Dis Colon Rectum. 1986 Apr;29(4):234-42 [3512199.001]
  • [Cites] Int J Colorectal Dis. 1991 Aug;6(3):152-7 [1744487.001]
  • [Cites] Clin Radiol. 2005 Oct;60(10):1111-9 [16179172.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Colorectal Dis. 1992 Sep;7(3):122-4 [1402307.001]
  • [Cites] Int J Colorectal Dis. 2007 Oct;22(10 ):1261-8 [17294198.001]
  • [Cites] Int J Colorectal Dis. 1991 Feb;6(1):2-4 [2033348.001]
  • [Cites] Dis Colon Rectum. 1978 Mar;21(2):89-91 [648293.001]
  • [Cites] Cancer Invest. 2006 Aug-Sep;24(5):535-44 [16939964.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jan;186(1):144-8 [16357394.001]
  • [Cites] Radiology. 2004 Sep;232(3):773-83 [15273331.001]
  • [Cites] Eur J Radiol. 2007 Mar;61(3):480-9 [17188828.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2491-9 [12815134.001]
  • [Cites] Int J Colorectal Dis. 2007 Nov;22(11):1347-52 [17643251.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Endoscopy. 2001 Mar;33(3):231-6 [11293755.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):191-9 [16799791.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] Int J Colorectal Dis. 1992 Dec;7(4):192-6 [1293239.001]
  • [Cites] Dis Colon Rectum. 1974 Mar-Apr;17(2):181-7 [4819268.001]
  • [Cites] Radiol Med. 2003 Oct;106(4):329-37 [14612825.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800 [17379452.001]
  • [Cites] Dis Colon Rectum. 1981 Mar-Apr;24(2):73-5 [7215078.001]
  • [Cites] Radiology. 2007 Jan;242(1):137-43 [17090719.001]
  • [Cites] J Ultrasound Med. 2006 Jan;25(1):57-73 [16371556.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Radiology. 1990 May;175(2):494-8 [2326475.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):92-102 [15629599.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19365694.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. de Bree E, van Ruth S, Dewit LG, Zoetmulder FA: High risk of colostomy with primary radiotherapy for anal cancer. Ann Surg Oncol; 2007 Jan;14(1):100-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High risk of colostomy with primary radiotherapy for anal cancer.
  • BACKGROUND: Radiotherapy (RT) has become the primary treatment of choice for anal cancer in an effort to avoid colostomy.
  • Early stage disease, low T-score and absence of infiltration in adjacent organs were associated with a reduced need for colostomy in univariate analysis.
  • CONCLUSIONS: In approximately one-third of the patients treated by anal sphincter saving management with curative aimed primary RT, the creation of a colostomy appeared to be necessary for RT complications and local treatment failure.
  • Therefore, patients should be well informed regarding the considerable risk of need for colostomy after RT for anal cancer.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Colostomy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual. Radiation Injuries / etiology. Radiation Injuries / surgery. Radiotherapy Dosage. Risk Factors. Treatment Failure

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17066231.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Hatzaras I, Abir F, Kozol R, Sullivan P, Longo WE: The demographics, histopathology and patterns of treatment of anal cancer in Connecticut: 1980-2000. Conn Med; 2005 May;69(5):261-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The demographics, histopathology and patterns of treatment of anal cancer in Connecticut: 1980-2000.
  • OBJECTIVES: Examine the epidemiology and clinical characteristics of anal cancer in the State of Connecticut.
  • MATERIALS AND METHODS: The Department of Health Connecticut Tumor Registry resources were utilized for the years 1980-2000.
  • RESULTS: A total of 646 anal cancers (410 females, 236 males) were diagnosed (mean age: 63.4 years).
  • CONCLUSIONS: Anal cancer incidence in Connecticut increased in the 21-year period 1980 to 2000, affecting the rate for African-American men more than other race-specific and gender-specific population subgroups.
  • Anal cancer affects women more often than men.
  • [MeSH-major] Adenocarcinoma / epidemiology. Anus Neoplasms / epidemiology. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Colectomy / methods. Combined Modality Therapy. Connecticut / epidemiology. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Registries. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16114640.001).
  • [ISSN] 0010-6178
  • [Journal-full-title] Connecticut medicine
  • [ISO-abbreviation] Conn Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Chen YW, Yen SH, Chen SY, Huang PI, Shiau CY, Liu YM, Lin JK, Wang LW: Anus-preservation treatment for anal cancer: retrospective analysis at a single institution. J Surg Oncol; 2007 Oct 1;96(5):374-80
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anus-preservation treatment for anal cancer: retrospective analysis at a single institution.
  • BACKGROUND: To evaluate anus-preservation treatment for anal cancer.
  • METHODS: Review of 42 patients (24 M/18 F; median age, 70 years; range, 13-95) with stage I-IIIB disease (squamous cell carcinoma [SqCC], 33; adenocarcinoma, 9) who received curative radiotherapy between 1991 and 2004.
  • Radiotherapy comprised lower-pelvis irradiation with boost to primary tumor (median lower-pelvis dose, 45 Gy; range, 17.2-59; median primary-site dose, 56 Gy; range, 40-72).
  • The complete response rate was 67% (SqCC, 23/33; adenocarcinoma, 5/9); of 12 patients who failed treatment, primary tumor was the recurrent site in seven (median failure time, 5 months): six patients underwent salvage abdominoperineal resection.
  • Three-year overall (OS) and disease-free survival (DFS) were 53% and 64%.
  • Five-year functional anus-preservation rate was 64%.
  • CONCLUSION: With careful monitoring of toxicity, non-surgical anus-preservation treatment with good tumor control is feasible.
  • [MeSH-major] Adenocarcinoma / therapy. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Multivariate Analysis. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17492635.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


99. Kawahara H, Watanabe K, Ushigome T, Noaki R, Kobayashi S, Yanaga K: Retrograde single stapling technique for laparoscopic ultralow anterior resection. Dig Surg; 2010;27(4):261-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After the anal side of the tumor has been closed transanally, the distal line in the right lateral wall of the rectum is partially transected with laparoscopic coagulation shears (LCS).
  • After an anvil is placed in the proximal end of the colon over a purse-string suture, it is introduced to the anal canal transabdominally.
  • For the prevention of anastomotic leakage, a 24-french balloon catheter which decompresses the anastomosis is inserted through the anus.
  • [MeSH-major] Laparoscopy / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery. Surgical Stapling / methods
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Anal Canal / surgery. Anastomosis, Surgical / methods. Anastomotic Leak. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Proctoscopy / methods. Risk Assessment. Sampling Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20668381.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


100. Donigan M, Loh BD, Norcross LS, Li S, Williamson PR, DeJesus S, Ferrara A, Gallagher JT, Baker CH: A metastatic colon cancer model using nonoperative transanal rectal injection. Surg Endosc; 2010 Mar;24(3):642-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The transanal model allows for further examination of systemic immune responses, tumor take, and onset of metastasis without prior surgical intervention.
  • METHODS: For this study, 60 Balb/c mice were anesthetized and subjected to gentle anal dilation using blunt-tipped forceps at the anal opening.
  • Tumor growth and metastatic development was monitored at 5-day intervals for 50 days.
  • The overall success of tumor growth in both experiments using the transanal rectal injection was 65%.
  • Histology showed that all tumors were poorly differentiated adenocarcinomas.
  • [MeSH-major] Colonic Neoplasms / secondary. Neoplasm Transplantation / methods. Rectum / pathology
  • [MeSH-minor] Anal Canal. Animals. Cell Line, Tumor. Disease Models, Animal. Injections / methods. Mice. Mice, Inbred BALB C

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Dig Surg. 2005;22(1-2):16-25 [15838167.001]
  • [Cites] Int J Cancer. 1989 Jul 15;44(1):177-81 [2744889.001]
  • [Cites] J Surg Res. 2009 Jun 15;154(2):299-303 [19101690.001]
  • [Cites] Cancer Res. 1975 Sep;35(9):2434-9 [1149045.001]
  • [Cites] Am J Pathol. 2007 Mar;170(3):1077-85 [17322390.001]
  • [Cites] Cancer Res. 1988 Apr 1;48(7):1943-8 [3349467.001]
  • [Cites] Arch Surg. 1995 Jun;130(6):649-53 [7763175.001]
  • [Cites] Surg Endosc. 2003 Jun;17(6):972-8 [12640542.001]
  • [Cites] Surg Endosc. 1998 Aug;12 (8):1092-5 [9685551.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Cancer Sci. 2004 Jun;95(6):514-9 [15182433.001]
  • [Cites] Eur J Surg Oncol. 2008 Apr;34(4):476-81 [17698312.001]
  • [Cites] Surg Oncol. 1992 Jun;1(3):251-6 [1341258.001]
  • [Cites] Int J Oncol. 2005 Jul;27(1):113-20 [15942650.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2556-61 [10873112.001]
  • (PMID = 19688392.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement